



## King's Research Portal

DOI:

[10.1371/journal.pbio.3002237](https://doi.org/10.1371/journal.pbio.3002237)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Felske, T., Tocco, C., Peron, S., Harb, K., Alfano, C., Galante, C., Berninger, B., & Studer, M. (2023). Lmo4 synergizes with Fezf2 to promote direct in vivo reprogramming of upper layer cortical neurons and cortical glia towards deep layer neuron identities. *PLoS Biology*, 21(8 August), [e3002237]. <https://doi.org/10.1371/journal.pbio.3002237>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

## **Lmo4 synergizes with Fezf2 to promote direct *in vivo* reprogramming of upper layer cortical neurons and cortical glia towards deep layer neuron identities**

Torsten Felske<sup>1@</sup>, Chiara Tocco<sup>1@</sup>, Sophie Péron<sup>2,3@</sup>, Kawssar Harb<sup>1</sup>, Christian Alfano<sup>1</sup>, Chiara Galante<sup>2</sup>, Benedikt Berninger<sup>2,3,4,5,#</sup> and Michèle Studer<sup>1,#,\*</sup>

<sup>1</sup>Université Côte d'Azur, CNRS, Inserm, iBV, Nice, France

<sup>2</sup>Research Group "Adult Neurogenesis and Cellular Reprogramming", Institute of Physiological Chemistry, University Medical Center Johannes Gutenberg University, Mainz, Germany

<sup>3</sup>Centre for Developmental Neurobiology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom

<sup>4</sup>MRC Centre for Neurodevelopmental Disorders, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom

<sup>5</sup>Focus Program Translational Neuroscience, Johannes Gutenberg University, Mainz, Germany

@These authors have contributed equally to the study.

#Co-last authors.

\* [michele.studer@unice.fr](mailto:michele.studer@unice.fr)

Short title : *In vivo* direct neuronal reprogramming *via* Fezf2 and Lmo4

### **ABSTRACT**

*In vivo* direct neuronal reprogramming relies on the implementation of an exogenous transcriptional program allowing to achieve conversion of a particular neuronal or glial cell type towards a new neuronal identity. The transcription factor *Fezf2* is known for its role in neuronal subtype specification of deep-layer subcortical projection neurons. In fact, high ectopic *Fezf2* expression in mice can convert both upper layer and striatal projection neurons

into a corticofugal fate, even if at low efficiency. In this study, we show that *Fezf2* synergizes with the nuclear co-adaptor *Lmo4* to further enhance reprogramming of upper-layer cortical pyramidal neurons into deep-layer corticofugal neurons, at both embryonic and early postnatal stages. Reprogrammed neurons express deep-layer molecular markers and project toward subcerebral targets, including the thalamus, cerebral peduncle, and spinal cord. We also show that *Fezf2* co-expression with the reprogramming factors *Neurog2* and *Bcl2* in early postnatal mouse glia promotes glia-to-neuron conversion with partial hallmarks of deep-layer neurons, and with *Lmo4* promoting further morphological complexity. These data support a novel role for *Lmo4* in synergizing with *Fezf2* during direct lineage conversion *in vivo*.

**KEYWORDS:** *Fezf2*, *Lmo4*, *in vivo* reprogramming, cortical glial cells, subcortical neurons

**BLURB:** 29 words

An *in vivo* study showing the fate determinant gene *Fezf2* synergizing with the co-adaptor *Lmo4* to reprogram upper layer cortical neurons or postnatal glia cells into corticofugal projection neurons.

## INTRODUCTION

While the mechanisms driving the acquisition of specific neuronal class and subtype identities are increasingly investigated, the maintenance of such identity and conversely the degree of plasticity of changing identity in the nervous system remains rather enigmatic [1]. Work over the last decade has challenged the view that neural cell identity is irrevocably fixed by demonstrating that fate-restricted neuronal progenitors and even early postmitotic neurons can be coaxed into neurons of distinct identities when appropriate transcriptional cues are provided [2-4], an experimental approach referred to as direct lineage reprogramming [5]. Likewise, different classes of glial cells, i.e. astrocytes, oligodendrocyte progenitor cells, and microglia can be converted into induced neurons by forced expression of neurogenic transcription factors (TFs) or regulatory *RNAs*, known to act as key regulators of cell fate during development [6, 7]. However, it is still not clear to which extent induced neurons generated by direct lineage reprogramming acquire authentic molecular signatures of the desired neuronal subtype or whether they share similar developmental trajectories, function, and connectivity with subtype-specific projections.

Although direct lineage reprogramming still inspires cell replacement therapy, it also includes major limitations that need to be overcome. First, molecular and cellular features of the starter cell type, as well as extracellular components may ease or impede the conversion process, and lineage-related cells might be easier to convert into each other as they share a common origin. For example, glial cells can be converted *in vitro* into functional neurons by overexpression of a single TF [8, 9], whereas *in vivo*, single-factor reprogramming is much more limited, often requiring additional stimuli such as tissue injury and glial cell reactivation [10-13]. Moreover, the same reprogramming factor can trigger different outcomes when induced in different cell types. For instance, *Neurog2* has been shown to convert cortical astrocytes into cortical-like glutamatergic neurons [9, 14], while thalamic and spinal astrocytes acquire thalamic relay neurons and spinal interneuron-like signatures, respectively [15, 16], and fibroblasts even adopt a cholinergic motor neuron-like cell fate [17]. Moreover, successful reprogramming may require co-factors that negotiate critical transitions in the cellular metabolism [18, 19]. Conversion of one postmitotic neuron subtype into another appears to be even more complex and limited to the very early stages of postnatal life. For instance, embryonic (E) 14.5 callosal projection neurons of cortical upper layers II-IV could be

converted into deep layers V/VI subcortical projection neurons *via* the forced expression of the TF *Fezf2*, but failed at later stages, i.e., after postnatal (P) day 3 [2, 4, 20, 21]. These observations point to the existence of tight crosstalk between reprogramming factors and the cellular context in which they operate and suggest that the epigenetic signature of the starting cell population may limit cellular plasticity and their response to reprogramming factors [22]. Thus, current research aims at identifying reprogramming roadblocks whose removal could improve reprogramming efficiency and accuracy [7]. For instance, during glia-to-neuron reprogramming, increased production of reactive oxygen species (ROS) can lead to cell death of induced neurons (iNs) *per* ferroptosis [18]. This has been partially overcome by allowing the expression of anti-cell death regulators, such as *Bcl2*, or by pharmacological treatments aimed at reducing reactive oxygen species. Simultaneous expression of *Neurog2* and *Bcl2* induced the reprogramming of non-neuronal cells into immature deep-layer pyramidal neurons [18].

To date, generating different neuronal subtypes of fully functional mature cells constitutes the major challenge in direct reprogramming [6, 23]. TFs commonly used in direct neuronal reprogramming typically possess pioneering activity, such as transiently engaging closed chromatin to initiate transcriptional programs leading to cell fate changes [24, 25]. However, they often fail to activate genes that are silenced by specific DNA and chromatin modifications [26]. Identifying co-factors that facilitate the binding of lineage-specific TFs on less accessible chromatin sites might improve reprogramming efficiency and specificity and stabilize neuronal identity. Therefore, one of the major aims of direct reprogramming becomes to identify novel factors conducive for generating specific neuronal subtypes.

Aiming at improving direct reprogramming efficiency and subtype specificity, first in immature neuronal cells and then in glial cells of the developing mouse cortex, here we used *Fezf2* as a well-established subcerebral determinant gene together with the co-adaptor *Lmo4*. *Lmo4* is known to work as an epigenetic and subtype-specific factor by acting through an HDAC-dependent mechanism in de-repressing the *Ctip2* locus [27-31]. We show that *Lmo4* synergizes with *Fezf2* in converting upper-layer neurons into deep-layer subcortical projection neurons at a higher efficiency than previously reported [2, 4]. We also find that *Fezf2* directs *Neurog2/Bcl2*-mediated reprogramming of early cortical glia into *Ctip2*-expressing iNs, while *Lmo4* further promotes their morphological complexity. Together, our data show that *Fezf2*

synergizes with the co-adaptor *Lmo4* in lineage reprogramming in both neurons and glia towards a deep layer cortical neuron fate.

## RESULTS

### ***Fezf2 acts synergistically with Lmo4 in converting upper- into deep-layer neurons during embryonic stages***

Previous data showed that overexpression of *Fezf2* in striatal progenitors or young postmitotic cortical upper layers II-IV neurons converts these neurons into deep layer (i.e., layer V/VI) corticofugal projection neurons (CFuPNs) [2, 4, 20, 21, 32]. Although reprogrammed neurons projected subcortically and acquired morphological and electrical properties characteristic of deep layer projection neurons, the efficiency of the cortical lineage conversion was between 20% and 30% dependent on the CFuPN marker used, and strongly diminished postnatally [2, 4]. We hypothesized that the nuclear co-adaptor and epigenetic factor *Lmo4* could be a good candidate for potentiating cell fate changes and improving conversion rates. Indeed, previous observations from our lab had shown that *Lmo4* over-expression leads to increased expression of the layer V marker *Ctip2* in deep layer neurons [31].

To test our hypothesis, we first performed *in utero* electroporation (IUE) to induce expression of our proposed reprogramming cocktail into embryonic *wild-type* mouse cortex. We took advantage of the *Cdk5r* gene promoter, which drives gene expression starting from the young post-mitotic stage of neuronal maturation [33], to restrict ectopic expression of *Lmo4* and/or *Fezf2* to postmitotic neurons. The reporter gene *Green Fluorescent Protein (GFP)* was used as a readout allowing proper visualization of the electroporated cells. A *Cdk5r-GFP (cGFP)* plasmid was used as control, whereas the *Cdk5r-Fezf2-IRES-GFP (cFezf2)* and the *Cdk5r-Lmo4-IRES-GFP (cLmo4)* plasmids mediated *Fezf2* and *Lmo4* gain-of-function, respectively [2, 31] (**Fig 1A**). Plasmids were then IUE into the primary somatosensory (S1) cortex of embryonic age (E)14.5 *wild-type* embryos and electroporated brains were analyzed at postnatal stage P7 (**Figs 1 and S1A**). *Cdk5r* promoter-driven gene expression became induced in migratory, postmitotic neurons and was then retained in differentiated and mature neurons (**Figs 1B and S1B**) [2, 34]. A panel of upper- and deep-layer (hereinafter named UL and DL, respectively)

molecular markers expressed at early or late cortical development was then assessed in electroporated brains: Cux1 for UL callosal neurons [35], Ctip2 and Pcp4 [36, 37], Fog2 and Darpp32 for DL neurons [38-40]. To better define the precise laminar and cell-type specificity of the markers, we first performed double-immunostaining for Fog2, Pcp4 and Darpp32 with the well-described layer V marker Ctip2 [36] in S1 of *wild-type* non-electroporated brains (**S1C Fig**). We found that 74% of Ctip2+ high-expressing cells in layer V co-expressed Pcp4, while only 4% co-expressed Fog2 and 9% Darpp32. Conversely, Ctip2+ low-expressing cells, predominantly localized in layer VI, were strongly positive for Fog2 (70%), Darpp32 (80%), and to a minor extent for Pcp4 (34%) (**S1C Fig and S1 Data**). These data confirm that high expression of Ctip2 or Pcp4 is a reliable readout of layer V neuron identity, while elevated levels of Fog2 and Darpp32 support a layer VI identity.

**Fig 1. Synergistic effect of Fezf2 and Lmo4 in upper- to deep-layer neuron reprogramming. (A)** Schematic representation of the experimental procedure and vectors. cGFP, cLmo4 (cL), cFezf2 (cF) or cFezf2 and cLmo4 (cF+cL) plasmids were electroporated into E14.5 somatosensory (S1) embryonic cortices. Brains were collected at P7. **(B)** Immunofluorescence (IF) of GFP, upper layer marker Cux1, and deep layer V marker Ctip2 on a coronal slice of a cFezf2 and cLmo4-electroporated brain. The white box indicates the magnification image on the right side. **(C)** Percentage of S1 electroporated UL neurons expressing upper versus deep layer markers. **(D)** Representative images of Cux1, Ctip2, Fog2, Pcp4, and Darpp32 IF staining in electroporated brains. Full and empty arrowheads indicate whether GFP+ cells co-express or not, respectively, the marker. To the right, confocal images of high-magnification panels showing three-dimensional reconstructions of double staining. Sidebars represent projections along the x-z axes (right) and the y-z axes (below). **(E)** Tract tracing of upper layer GFP+ axons upon electroporation of cGFP, cFezf2 or cFezf2 and cLmo4 in P7 brains. In control cases, the vast majority of GFP+ axons cross the corpus callosum (CC) to reach the contralateral hemisphere. In cFezf2-electroporated brains, fewer GFP+ axons cross the CC, and many are found in the striatum (Str) and subcerebral targets, such as internal capsule (IC), thalamus (Th), cerebral peduncle (CP) and spinal cord (SC). In cFezf2 and cLmo4-electroporated brains, no projections are observed along the CC, and almost all GFP+ axons project through the Str to subcerebral targets. White boxes indicate the regions magnified in the panels below. Full and empty arrows indicate the presence or absence of axons, respectively. Scale bars: C= 1000 $\mu$ m (left, macro image) and 200 $\mu$ m (right, magnified image); D= 20 $\mu$ m; E= 1000 $\mu$ m (top row, macro images), 200 $\mu$ m (magnified images). Results are expressed as mean  $\pm$  s.e.m. Two-way ANOVA with Tukey's post-hoc correction was used for statistical analysis, \* $p$ <0.05 \*\* $p$ <0.01 \*\*\* $p$ <0.001.  $n$  = 3 brains for each plasmid. Extended data and statistics are listed in **S1 Data**.

Then, we evaluated the reprogramming potential of *Lmo4* alone before combining it with *Fezf2* (**S2A-B Fig**). Ectopic expression of c*Lmo4* alone in electroporated UL neurons revealed that the percentage of GFP+ neurons expressing Cux1 was very similar to cGFP controls at P7 (**Figs 1C and S2C-D and S1 Data**), and that c*Lmo4* alone failed to induce any layer V markers in UL GFP+ neurons, even if a few GFP+ cells expressed the layer VI markers Fog2 and Darpp32

(S2C-D Fig and S1 Data). Accordingly, P7 tract-tracing analysis of GFP+ neurons in E14.5 *cLmo4*-electroporated brains revealed GFP+ axons projecting through the corpus callosum (CC) towards the contralateral hemisphere, with very few axons projecting ipsilaterally to the striatum, similarly to *cGFP*-electroporated brains (S2E Fig). No projections were observed towards subcerebral targets, such as the thalamus, cerebral peduncle, and spinal cord, indicating that ectopic expression of *cLmo4* alone at E14.5 does not lead to any evident changes in molecular identity and axonal connectivity of UL neurons.

We next hypothesized that the combined activity of *Lmo4* (as a *Ctip2* de-repressor) with *Fezf2* (as a *Ctip2* inducer) would improve *Fezf2*-driven reprogramming efficiency of S1 UL neurons into CFuPNs. The *cFezf2* plasmid was electroporated together with *cLmo4* at E14.5 (Fig 1A-B), and high *Lmo4* and *Fezf2* levels were confirmed in electroporated brains with almost 90% of GFP+ cells expressing both proteins (S1A-B Fig). Quantification of the percentage of GFP+ cells expressing UL and DL markers in *cFezf2*-electroporated brains showed an 83% decrease in *Cux1*-expressing cells compared to control *cGFP*-electroporated brains, and a concomitant increase of *Ctip2*+ (35%), *Fog2*+ (21%), *Pcp4*+ (28%) and *Darpp32*+ (56%) neurons (Fig 1C-D and S1 Data). Remarkably, the co-electroporation of *cFezf2* and *cLmo4* produced an almost double increase of GFP+ cells expressing *Ctip2* (64%) and *Pcp4* (54%), but no significant further changes of GFP+ cells expressing *Cux1*, *Fog2* and *Pcp4* cells when compared to *cFezf2*-electroporated cells (Fig 1C-D and S1 Data), suggesting that *Lmo4* endorses electroporated cells to predominantly acquire a layer V-like identity. Remarkably, in agreement with the changed molecular identities, GFP+ axons were observed in the striatum (Str), thalamus (Th), internal capsule (IC), cerebral peduncle (CP), and to a minor extent even in the spinal cord (SC) of both *cFezf2*- and double *cFezf2/cLmo4*-electroporated cortices (Fig 1E and Table 1). Interestingly, no callosal axons projecting contralaterally were found in *cFezf2/cLmo4*-electroporated brains, suggesting that induced co-expression of *cLmo4* and *cFezf2* in UL neurons strongly inhibited axon midline crossing. Taken together, these data indicate that *Lmo4* synergistically acts with *Fezf2* in reprogramming UL to DL neurons, particularly into layer V *Ctip2*+ *Pcp4*+ neurons, by inducing an almost complete redirection of UL projections to corticofugal targets.

***Reprogramming of upper into layer V neurons by Fezf2 and Lmo4 is more efficient in primary motor than somatosensory cortex***

We next investigated whether the cortical environment could impact UL to DL conversion. Since the primary motor area (M1) differs in its cytoarchitecture from S1 cortex by containing a higher number of layer V Ctip2+ neurons [41, 42], we hypothesized that M1 might provide an even more conducive environment for layer V reprogramming of UL neurons. To examine this possibility, E14.5 embryos were electroporated with *cGFP*, *cLmo4*, *cFezf2* or *cFezf2/cLmo4* plasmids into the presumptive motor area and brains analyzed at P7 (**Fig 2A**). Targeted GFP+ M1 post-mitotic UL neurons (**Fig 2B**) were assessed for expression of UL and DL markers and then compared to S1-electroporated neurons (**Fig 2C-E**). As for S1, ectopic expression of *cLmo4* alone did not result in any lineage conversion, but the combined expression of *cFezf2* with *cLmo4* in M1 resulted in a 92% reduction of the GFP/Cux1+ cells and an almost 80% increase of the GFP/Ctip2+ and 60% of the GFP/Pcp4+ cell populations, compared to the presence of 78% Cux1+ UL neurons versus 34% Ctip2+ and 23% Pcp4+ DL-like neurons in *cFezf2*-electroporated brains (**Fig 2C and S2 Data**). No statistical differences were observed in the number of layer VI Fog2+ and Darpp32+ cells between *cFezf2* and *cFezf2/cLmo4* GFP+ electroporated cells (**Fig 2C and S2 Data**), strongly supporting a synergistic effect of *Lmo4* with *Fezf2* in reconvertng UL into layer V-like projection neurons. In addition, our data show that cell lineage conversion was more efficient in M1 than S1, particularly regarding the GFP/Ctip2+ cells which increased from 64% in S1 to almost 80% in M1 in double *cFezf2/cLmo4* UL GFP+ cells. No significant changes between S1 and M1 were observed for Fog2+ cells (**Fig 2D-E and S2 Data**). These data strongly indicate that *Lmo4/Fezf2* co-expression leads to higher reprogramming efficiency in M1 than in S1.

***Fig 2. Reprogramming of upper layers into layer V neurons by Fezf2 and Lmo4 is more efficient in motor than somatosensory cortex.*** (A) Schematic representation of the experimental procedure. *cGFP*, *cLmo4* (*cL*), *cFezf2* (*cF*) or *cFezf2* and *cLmo4* (*cF+cL*) plasmids were electroporated into E14.5 motor (M1) cortices. Brains were collected at P7. (B) Immunofluorescence (IF) of GFP, upper layer marker Cux1, and deep layer V marker Ctip2 on a coronal slice of a *cF+cL*-electroporated brain. The white box indicates the magnification image on the right side. (C) Percentage of M1 electroporated-UL neurons expressing upper versus deep layer markers. (D-E) Percentage of S1 versus M1 electroporated UL neurons expressing layer V marker Ctip2 (D) and layer VI marker Fog2 (E). Scale bars: B= 1000 $\mu$ m (left, macro image), 200 $\mu$ m (right, magnified image). Results are represented as mean  $\pm$  s.e.m. Two-way ANOVA with Tukey's post-hoc correction (2C) or Two-way ANOVA with Sidak's post-hoc correction (2D-

E) was used for statistical analysis. \* $p < 0.05$  \*\* $p < 0.01$  \*\*\* $p < 0.001$ , ns = not significant.  $n = 3$  brains for each plasmid. Extended data and statistics are listed in **S2 Data**.

This suggests that either the environment and/or the intrinsic cell competence of M1 are more conducive towards *Fezf2*-dependent layer V lineage conversion, in line with its expanded expression and a larger representation of subcerebral layer V projection neurons in M1 than in S1 during physiological development [43]. Even though M1 produced a slightly better conversion, S1 remained our choice of preference for the following experiments due to its high accessibility that grants more reliable and reproducible electroporation sites, and linked analyses.

### **Reprogramming of UL into LL neurons by *Fezf2* and *Lmo4* is maintained until P35**

To assess whether the neuronal lineage conversion was a transient effect or stably maintained at later stages, E14.5 embryos were electroporated with *cGFP*, *cLmo4*, *cFezf2* or *cFezf2/cLmo4* plasmids (**Fig 3A**) and the percentage of GFP+ neurons expressing UL and DL markers was determined at P35 and compared with those obtained at P7 (**Fig 3B-G**). As expected, in control *cGFP*-electroporated brains, *Cux1* expression was detected in almost all GFP+ UL neurons, both postnatally (P7) and at more mature stages (P35). In contrast, the number of GFP/*Cux1*+ cells among *cFezf2*- and *cFezf2/cLmo4*-electroporated UL neurons remained consistently low at P35 (**Fig 3C and S3 Data**). Similarly, no changes in the number of GFP/*Fog2*+ and GFP/*Pcp4*+ cells were observed between P7 and P35 in control, *cFezf2*, and *cFezf2/cLmo4* electroporated brains (**Fig 3E and 3F and S3 Data**). Conversely, the number of GFP/*Darpp32*-expressing significantly dropped in *cFezf2*, and *cFezf2/cLmo4* electroporated brains (**Fig 3G and S3 Data**). Finally, the rate of GFP/*Ctip2*+ UL neurons remained constant between P7 and P35 in both control *cGFP*- and *cFezf2*-electroporated brains (between 36% and 38%), whereas it slightly decreased from 64% to 43% in *cFezf2/cLmo4*-electroporated UL neurons (**Fig 3D and S3 Data**). Overall, our data show that most of the E14.5-reprogrammed UL neurons keep their newly acquired layer V/VI-like molecular signature over time.

**Fig 3. Reprogramming of upper into deep layer neurons by *Fezf2* and *Lmo4* is maintained until P35.** (A) Schematic representation of the experimental procedure. *cGFP*, *cL*, *cF* or *cF+cL* plasmids were electroporated into E14.5 somatosensory (S1) cortices. Brains were collected at P35. (B) Schematics of a coronal section of a brain showing in red the area (somatosensory cortex S1) from which the IF images below have been taken. Representative IF images of *Cux1*, *Ctip2*, *Fog2*, *Pcp4*, and *Darpp32*

staining in cGFP, cF and cF+cL electroporated brains. Full and empty arrowheads respectively indicate whether GFP+ cells co-express the indicated marker. (C-G) Percentage of S1 electroporated UL neurons expressing upper versus deep layer markers compared between P7 and P35 brains. Scale bars: B= 20µm. Results are represented as mean ± s.e.m. Two-way ANOVA with Sidak's post-hoc correction was used for statistical analysis. \*p<0.5 \*\*\*p<0.001, ns = not significant. n = 3 brains for each plasmid. Extended data and statistics are listed in **S3 Data**.

### **Postnatal induction of Fezf2 and Lmo4 expression**

Given the high efficiency of *Fezf2* and *Lmo4* in reprogramming postmitotic UL neurons at embryonic stages, we next tested their potential at postnatal stages (**Fig 4**). To this purpose, we subcloned *Fezf2* or *Lmo4* into the inducible vector *pCAG-fl-mutCherry-fl-IRES-EGFP* [44] resulting in *pCAG-Ind-GFP (iGFP)*, *pCAG-Ind-Fezf2 (iFezf2)* and *pCAG-Ind-Lmo4 (iLmo4)* (**Fig 4A**). All vectors were co-electroporated with the *pCAG-CRE-ERT<sup>2</sup>* plasmid at E14.5, and 4-hydroxytamoxifen (TAM) was administrated at different postnatal stages to drive *Cre*-recombinase activation [45].

**Fig 4. Postnatal induction of Fezf2 and Fezf2/Lmo4 expression promotes layer V and inhibits upper-layer neuron identity.** (A) Representation of the experimental vectors used in B and D. *iGFP*, *iFezf2 (iF)* or *iFezf2* and *iLmo4 (iF+iL)* were electroporated into E14.5 somatosensory (S1) cortices. (B) Schematics of a coronal section of a brain showing in red the area (somatosensory cortex S1) from which the IF images in C and E have been taken. (C) Gene expression was induced at P3 by tamoxifen subcutaneous injection. Brains were collected at P8. Representative IF images of *Cux1*, *Ctip2*, *Fog2*, *Pcp4*, and *DarppP32* staining in *iGFP*, *iF* and *iF+iL* electroporated brains. Full and empty arrowheads respectively indicate GFP+ cells co-expressing or not the indicated marker, respectively. (D) Percentage of S1 electroporated UL neurons expressing upper versus deep layer markers. (E) Gene expression was induced at P7 by tamoxifen subcutaneous injection. Brains were collected at P14. *iGFP*, *iFezf2 (iF)* or *iFezf2* and *iLmo4 (iF+iL)* together with *pCAG-CRE-ERT<sup>2</sup>* were electroporated into the E14.5 S1 cortex. Representative IF images of indicated marker staining in *iGFP*- and *iFL*-electroporated brains. Full and empty arrowheads indicate GFP+ cells co-expressing or not the indicated marker. (F) Percentage of S1 electroporated UL neurons expressing upper versus deep-layer markers. Scale bars: B, E = 20µm. Results are represented as mean ± s.e.m. Two-way ANOVA with Sidak's post-hoc correction was used for statistical analysis. \*\*p<0.01 \*\*\*p<0.001, ns = not significant. n = 3 brains for each plasmid. Extended data and statistics are listed in **S4 Data**.

To validate our system and confirm that *iFezf2* and *iLmo4* could drive the expression of their respective proteins in electroporated GFP+ cells, TAM was injected at P3 in E14.5 electroporated mice and brains were collected at P8 (**S3A-B Fig**). Almost all cells were expressing *Fezf2* and *Lmo4* in TAM-induced neurons (**S3C Fig**). To ensure that these vectors were not inducing their respective proteins without TAM administration, we co-

electroporated an mCherry, *Cre*-independent plasmid together with *iFezf2/iLmo4* and *pCAG-CRE-ERT<sup>2</sup>* and analyzed the expression of GFP (*Cre*-dependent) and mCherry (*Cre*-independent) reporters. No GFP signal was found in mCherry<sup>+</sup> cells (**S3D Fig**), demonstrating that no unspecific activation of the inducible plasmids had occurred.

Next, we electroporated embryo brains at E14.5 with either *iGFP*, *iFezf2* or *iFezf2/iLmo4* and induced expression of these genes at P3 *via* injection of TAM (**Fig 4A-C**). Even at that postnatal stage, *iFezf2/iLmo4* expression resulted in a 45% decrease of GFP<sup>+</sup> cells expressing *Cux1* as compared to control *iGFP*, and in a 23% reduction compared to *iFezf2* induction in S1 cortex (**Fig 4B-D and S4 Data**). In line with previous observations [2, 4], postnatal induction of either *iFezf2* or *iFezf2/iLmo4* did not lead to a significant increase in the *Ctip2*<sup>+</sup> cell population, nor did it influence the number of *Fog2*<sup>+</sup> and *Darpp32*<sup>+</sup> cells in all electroporated conditions (**Fig 4C-D and S4 Data**). Instead, expression of *iFezf2/iLmo4* was able to boost the number of GFP<sup>+</sup> cells expressing the late layer V marker *Pcp4* to 67% when compared to *iFezf2* alone, which only induced 24% of GFP<sup>+</sup> cells to express *Pcp4* (**Fig 4C-D and S4 Data**). This implies that the co-expression of *Lmo4* allowed substantially more GFP<sup>+</sup> cells to express *Pcp4*. To further assess the reprogramming potential of *iFezf2/iLmo4* at later stages, we repeated the same experiment by injecting TAM at P7 and analyzing the brains at P14 (**Figs 4E-F and S4**), and TAM at P10 and analyzing the brains at P21 (**S5 Fig**). Interestingly, we could observe a reduction of GFP/*Cux1*<sup>+</sup> cells to 63% and a remarkable increase of GFP/*Pcp4*<sup>+</sup> to 49% in *iFezf2/iLmo4*-induced cells compared to control *iGFP* upon injection of TAM at P7 (**Fig 4E-F and S4 Data**).

These data show that the synergistic effect of *iFezf2* and *iLmo4* allows a higher number of cells to adopt a DL-like identity when compared to *iFezf2* alone (**Fig 4**) [2, 4]. Notably, the percentage of reprogrammed GFP<sup>+</sup> cells expressing *Pcp4* was even higher than in embryonic reprogramming experiments, confirming a preferentially postnatal expression pattern for *Pcp4* in CFuPN development, as previously suggested [36]. Taken together, the reprogramming cocktail of *iFezf2* and *iLmo4* revealed remarkable molecular identity alterations when induced at P3 and P7 in UL neurons, confirming a robust synergistic effect of both factors in reprogramming postnatal cortical projection neurons.

***Postnatal induction of double iFezf2/iLmo4 expression drives upper-layer neurons to change***

### ***their axonal projections toward subcerebral targets***

To further assess the potential of *Fezf2* and *Lmo4* in converting UL to DL neurons at postnatal stages, we followed reprogrammed GFP+ axonal projections. To facilitate tract tracing and obtain a stronger axonal signal of electroporated neurons in postnatal stages, we took advantage of the *pCAG-smFP\_FLAG* plasmid, which encodes multiple copies of the epitope tag FLAG [46]. The so-called “spaghetti monster” protein does not emit any fluorescence on its own but can be easily detected by using an anti-FLAG antibody. After co-electroporating either *iGFP*, *iFezf2*, or *iFezf2/iLmo4* together with the *pCAG-CRE-ERT<sup>2</sup>* and *pCAG-smFP\_FLAG* plasmids at E14.5, transgene expression was induced by TAM injection at P3, P7 and P10, and brains collected at P8, P14 and P21, respectively (**Figs 5A and S4-S5**). In all conditions, we could detect FLAG+ axons along the CC and in the striatum, although fibers along the CC of *iFezf2/iLmo4*-electroporated brains appeared less organized (**Fig 5B**, see arrows in CC). Remarkably, several axons were detected in the IC, CP and SC of *iFezf2*- and *iFezf2/iLmo4*-electroporated brains with FLAG+ bundles more prominent in the CP and SC upon *iFezf2/iLmo4* than just *iFezf2* induction (**Figs 5B and S4** full arrows in CP and SC), suggesting a higher efficiency of axonal rerouting in the presence of *Lmo4* (**Table 1**). Few FLAG+ axons were found in the thalamus in all conditions (**Figs 5 and S4-S5**), indicating that reprogrammed neurons tend to follow a subcerebral trajectory rather than a corticothalamic one, in line with the higher number of GFP/*Pcp4*+ layer V-like neurons as compared to the number of GFP/*Fog2*+ and GFP/*Darpp32*+ layer VI-like neurons (**Fig 4**). Compared to P3, TAM induction at P7 and P10 still promoted some FLAG+ axons to reach the CP, and particularly upon *iFezf2/iLmo4* expression to reach the SC, although at progressively lower efficiency (**Table 1 and S4 and S5 Figs**). Finally, we challenged the competence of UL neurons to undergo reprogramming at even later postnatal stages by inducing expression of *iGFP*, *iFezf2* or *iFezf2/iLmo4* at P21 and collecting the electroporated brains at P35 (**S6A Fig**). Since no DL markers were induced at this stage, we limited our analysis to FLAG+ axonal trajectories. Induction at P21 showed axonal projections crossing the CC with ipsilateral projections reaching the striatum in all conditions (**S6B Fig**). While no signal was detected in the thalamus, FLAG+ axons could be observed in the IC of all electroporated conditions. Notably, a clear axonal signal was detected in the CP and SC of *iFezf2*- and even stronger in that of *iFezf2/iLmo4*-induced brains (**Table 1**), indicating that even at this late postnatal stage

reprogrammed UL neurons can still be instructed to change their axonal projections towards subcerebral targets.

**Fig 5. Postnatal induction of *Fezf2* and *Lmo4* expression drives upper-layer neurons to change their axonal projections toward subcerebral targets.** (A) Schematic representation of the experimental procedure and vectors. *iGFP*, *iFezf2* (*iF*) or *iFezf2* and *iLmo4* (*iF+iL*) together with *pCAG-CRE-ERT2* were electroporated into E14.5 somatosensory (*S1*) cortices. The *smFP-Flag* reporter plasmid was co-electroporated to facilitate axonal tracing. Gene expression was induced at P3 by tamoxifen subcutaneous injection. Brains were collected at P8. (B) Tract tracing of upper layer FLAG+ axons upon electroporation of indicated plasmids. FLAG+ axons were found crossing the corpus callosum (CC) and reaching the striatum (*Str*), thalamus (*Th*) and internal capsule (*IC*) in all conditions but projecting towards the cerebral peduncle (*CP*) and spinal cord (*SC*) only in *iF*- and *iF+iL*-electroporated brains. Note that GFP+ cells in the *Str* of *iGFP* and *iF* are electroporated ectopic cells and not axons. White boxes indicate regions magnified in the panels below or aside. Full and empty arrows indicate the presence or absence of axons, respectively. Scale bars: B = 20 $\mu$ m. n = 3 brains for each plasmid.

### ***Fezf2* promotes acquisition of deep layer-like hallmarks in neurons induced from glia**

We next investigated whether the subtype specifying roles of *Fezf2* and *Fezf2/Lmo4* could extend beyond the cellular context of neuron-to-neuron conversion and work also in glia-to-neuron reprogramming. Towards this end, we injected retroviruses encoding *Fezf2* and *Fezf2/Lmo4* (*CAG-Fezf2-IRES-GFP* or *Fezf2-P2A-Lmo4-IRES-GFP*) alone or in combination with a retrovirus encoding *Neurogenin2* (*Neurog2*) and *B-cell lymphoma 2* (*Bcl2*) (*Neurog2-T2A-Bcl2-IRES-DsRed*), previously shown to reprogram cortical glia into induced neurons [15], into the cerebral cortex of P5 mice. Moloney murine leukemia virus (MMLV)-based retroviruses were used for gene delivery in the postnatal cerebral cortex with the rationale that they selectively transduce cells undergoing mitosis [47] and thereby enable specific targeting of cortical glia undergoing proliferation [48]. Indeed, we have recently shown that retrovirus-targeted cells comprise by and large astrocytes (approximately 65%) and oligodendrocyte progenitors (roughly 35%), with very few other targeted cells [49] (**Fig 6**). First, we assessed overall glia-to-neuron conversion following transduction with *Neurog2-Bcl2* and/or *Fezf2* (*NBF*) 12 days after injection (**Fig 6A**). Consistent with the previously reported reprogramming of immature glia and adult reactive glia by *Neurog2-Bcl2* (*NB*) [15, 18] into induced neurons (iNs), we found *NB*-transduced cells (RFP+ cells) expressing doublecortin (DCX) (**Fig 6B and 6G**) indicating that retrovirus-induced conversion involved an immature neuron-like stage. In contrast, *Fezf2* expression alone (GFP+) had only a marginal effect on the number of DCX+ cells among the retrovirus-targeted cells and most cells exhibited a glial morphology (**Fig 6B**

**and 6G**). However, the percentage of cells losing glial morphology and expressing DCX increased to more than 80% following co-expression of *Fezf2* together with *Neurog2* and *Bcl2* (*NBF*) (RFP/GFP+ cells in **Fig 6B and 6G and S5 Data**). For both *NB*- and *NBF*-transduced cells, the conversion rate (i.e., DCX+ among reporter+ cells) was not affected by their depth relative to the cortical surface (**Figs 6H and S7 and S5 Data**), suggesting that residing in a particular cortical layer does not affect reprogramming efficiency. We next assessed whether iNs acquired a DL-like identity by assessing *Ctip2* expression (**Fig 6C and 6F**). As expected, endogenous *Ctip2* immunoreactivity was predominantly detected in nuclei located in deep cortical layers (**Fig 6C**). Our analysis revealed that less than 5% of the *NB*-transduced cells expressed *Ctip2* (**Fig 6C and 6F and S5 Data**). Strikingly, the proportion of cells expressing *Ctip2* was more than 4 times higher among *NBF*-transduced cells as compared with *NB*-transduced cells (**Fig 6C and 6F and S5 Data**). Intriguingly, *Fezf2*-induced specification into *Ctip2*+ iNs seemed to be facilitated in deep cortical layers enriched in endogenous *Ctip2*+ neurons. In fact, 30% of *NBF*-transduced cells located in deep cortical layers were *Ctip2*+ as compared to 15% of *NBF*-transduced cells in upper cortical layers (**Fig 6F and S5 Data**). We next analyzed reprogramming following transduction with *NB* together with *Fezf2-Lmo4* (*NBFL*). Co-expression of *Fezf2* and *Lmo4* in the absence of *Neurog2* and *Bcl2* was highly inefficient in inducing DCX expression in transduced cells (**Fig 6D and G**). However, as seen with *NBF*, we found that upon *NBFL* expression reprogramming into DCX-positive iNs was very efficient and indistinguishable between upper and deep cortical layers (**Fig 6H**). The percentage of DCX-positive cells was increased by 83% among *NBFL*-transduced cells as compared to *NB*-transduced cells, while it was very similar to *NBF* overexpression (**Fig 6D and 6G and S5 Data**). Our analysis further showed that many iNs expressed the mature neuronal marker NeuN throughout all cortical layers, without significant differences between *NB*, *NBF*, or *NBFL* conditions, while *Fezf2* or *Fezf2/Lmo4* alone failed to induce conversion into NeuN+ cells (**Fig 6E and 6G**). Together, our data indicate that while *NB* can reprogram P5 proliferative cortical glia with good efficiency, the additional expression of *Fezf2* (alone or in combination with *Lmo4*) further enhances glia-to-neuron conversion and, importantly, instructs iNs to acquire layer V-like molecular hallmarks.

**Fig 6. *Fezf2* promotes a layer V-like fate in neurons induced from glia by Neurog2-Bcl2.** (A) Schematic representation of the experimental design. Postnatal day 5 (P5) proliferative glia was targeted for reprogramming by injection of retroviruses encoding *Neurog2-Bcl2-DsRed* (*NB*) together with *Fezf2*-

GFP (NBF) or *Fezf2-Lmo4-GFP* (NBFL). Analysis was performed 12 days later. Middle, schematics of a coronal section of a brain outlined in red the area of imaging. (B) Numerous NB- and NBF-transduced cells express the immature neuronal marker DCX. Arrowheads show examples of DCX-expressing reprogrammed neurons. (C) Deep cortical (DL) layers are enriched in *Ctip2*-positive cell nuclei as compared with upper layers (UL). Some NB- and NBF-transduced cells express *Ctip2*. Solid-line arrowheads and dotted-line arrowheads show examples of *Ctip2*-positive and *Ctip2*-negative transduced cells, respectively. (D) Numerous NB- and NBFL-transduced cells express the immature neuronal marker DCX. Arrowheads show examples of DCX-expressing reprogrammed neurons. (E) In all cortical layers, numerous NB- NBF- and NBFL-transduced cells express the mature neuronal marker NeuN. Arrowheads show examples of NeuN-expressing reprogrammed neurons. (F) Quantification of the percentage of *Ctip2* expressing cells among NB- and NBF-transduced cells. The percentage of *Ctip2*-expressing cells among NBF-transduced cells is increased as compared with NB-transduced cells, predominantly in deep cortical layers. Mean  $\pm$  SD; Welch-ANOVA test; n=3 brains, 676 cells analysed (G) Quantification of the percentage of DCX-expressing (left) or NeuN-expressing (right) cells among GFP+ (F or FL), RFP+ (NB) and RFP+GFP+ (NBF or NBFL) cells. The percentage of DCX-expressing reprogrammed neurons is moderately increased in NBF- and NBFL-transduced cells as compared with NB-cells. Mean  $\pm$  SD; One-Way ANOVA followed by Tukey post-hoc test; n=3 brains/retrovirus combination, 2827 (DCX) and 1550 (NeuN) cells analysed (H) Quantification of the percentage of RFP+ (NB) and GFP+RFP+ (NBF or NBFL) cells expressing DCX at different depth relative to the cortical surface indicates similar reprogramming efficiency in upper and deep cortical layer. Mean  $\pm$  SD; Kruskal-Wallis test; n=3 brains/retrovirus combination, 2324 cells analysed. Extended data and statistics are listed in **S5 Data**.

#### **Increased dendritic complexity of iNs co-expressing *Fezf2* and *Lmo4***

In light of the role of *Fezf2* promoting not only subcortical axonal projections from DL pyramidal neurons but also their dendritic morphology [50, 51], we investigated the dendritic complexity of NBF and NBFL iNs, by analyzing several distinct morphological parameters of iN distributed throughout upper and deep cortical layers at 12 dpi (**Fig 7A-E**). We first evaluated the dendritic arborization geometry and complexity (**Fig 7F**), by assessing the number of primary dendrites and branch points, total dendrite length, and dendrite order distribution (**S6 Data**). This analysis revealed an overall increased dendritic complexity of NBFL-reprogrammed glia as compared to NB and NBF iNs. While the addition of *Fezf2* already increased the number of primary dendrites compared to NB iNs, the combined expression of both *Fezf2* and *Lmo4* led to a further rise in the number of primary dendrites and branch points (**Fig 7F**) and resulted on average in improved higher-order dendrites (**Fig 7G**) and increased dendritic length (**Fig 7F**) as compared to NB and NBF iNs (**S6 Data**).

Finally, we determined Sholl profiles of NB, NBF and NBFL iNs (**Fig 7H and S6 Data**). Notably, the addition of *Fezf2* alone was sufficient to promote basal dendrite complexity (10-20 $\mu$ m from the soma) compared to control NB iNs. However, co-expression of *Lmo4* along with *Fezf2* induced a further increase in dendritic complexity (10-40 $\mu$ m from the soma).

Together, these data show that the *NBF* and *NBFL* gene combinations not only improve reprogramming efficiency towards a layer V-like neuron identity (**Fig 6**) but also promote the acquisition of more complex morphological features (**Fig 7**), suggesting a more mature state of reprogrammed neurons.

**Fig 7. Neurons induced by *NBF* and *NBFL* show increased dendrite complexity.** (A,B) Representative images of injection sites at 12dpi. Magnifications and 3D reconstructions (C,D,E) of NB, NBF and NBFL iNs, respectively. (F) Schematic representation of the analyzed morphological parameters. Blue dots represent primary dendrites, defined as filaments originating from the soma; green dots the branching points and numbers indicate the order of each terminal dendrite, defined as the number of branching points the dendrite undergoes from its somatic origin to the terminal tip. Average values (histogram bars) and data distribution (dot plot) of number of primary dendrites, branching points and total dendritic length for NB (grey), NBF (light blue) and NBFL (red) iNs, respectively. While NBF iNs only show an increase in primary dendrites compared to NB iNs, the addition of *Lmo4* (*NBFL*) induces a stronger effect, reflected by an increased number of primary dendrites, branching points, and increased overall dendritic length. (G) Histogram representing the dendrite order distribution in NB, NBF and NBFL iNs. Compared to NB neurons, NBF iNs show a significant increase in order 0 dendrites only, and a positive tendency in other categories (1-7). However, the addition of *Lmo4* (*NBFL*) leads to an increased number of 0-3 order dendrites, and a positive tendency in higher ranks (4-7) dendrites. (H) Sholl analysis of NB (grey), NBF (light blue) and NBFL (red) iNs points to increased overall complexity of dendrite arborization in NBFL compared to both NB and NBF. In the inset, a schematic representation of the analysis. Grey hashtags indicate statistical differences between NB-NBF and NB-NBFL and light blue hashtags between NBF-NBFL. Data are represented as mean  $\pm$  SEM. N=3 animals per condition. (F,G) Analysed cells: NB n= 283; NBF n= 89; NBFL n= 75. \*,  $p<0.05$ ; \*\*,  $p<0.01$ ; \*\*\*,  $p<0.005$ . Extended data and statistics are listed in **S6 Data**.

## DISCUSSION

### Neuron subclasses reprogramming by *Fezf2* and *Lmo4*

Several reports have shown that proliferating and differentiating postmitotic cell types can be reprogrammed to acquire specific features of a different lineage following the expression of TFs of alternative cell fates (reviewed in [5-7, 52]). However, the efficiency of lineage conversion, subtype specificity, and the maturation stage at which neurons are reprogrammed can vary in function of the TF cocktail, different experimental setup, and cell types. By taking advantage of the ability of the TF *Fezf2* to convert callosal projection neurons or cortical stellate neurons to corticofugal projection neurons [2, 4, 21], our data have unveiled a higher reprogramming efficiency of UL neurons than previously reported. We found that the co-expression of *Fezf2* with the co-adaptor *Lmo4* strongly increases the reprogramming competence of UL to acquire a layer V-like identity. Such conversion can rise to 80% when the process occurs in a more conducive environment, such as the motor cortex. This implies that even if *Fezf2* is considered a strong layer V determinant gene that represses

alternative cell-type specific genes [51, 53], it nevertheless might lack a significant pioneer factor activity on its own, and requires a favorable epigenetic and/or transcriptional context to optimally transcribe its target genes. Indeed, the recently described role of *Fezf2* during astrocyte maturation seems to be dependent on the chromatin state of the cell that expresses it [54]. Although we still do not know the exact mechanisms by which *Lmo4* improves *Fezf2*-mediated conversion, we postulate that *Lmo4* might act as a chromatin modifier of the epigenetic landscape of distinct fate-restricting signals by de-repressing factors that counteract fate changes, as shown in our previous work [31]. Indeed, while the *Ctip2* locus becomes normally silenced in the presence of a multiprotein complex including *Satb2*, HDAC and/or *Ski* [55-57], high levels of *Lmo4* prevent its assembly and release *Ctip2* repression [31]. Although *Lmo4* is considered a late layer V callosal projection neuron marker [28], it is also expressed in subcerebral neurons during early development and promotes layer V projection neuron fate in motor cortex [29]. This suggests that *Lmo4* may cooperate with several factors involved in the maturation and refinement of layer V projection neurons. In fact, overexpression of *Lmo4* alone is not sufficient to convert upper- into deep projection neurons (this study), indicating that it needs to work with selector regulators, such as *Fezf2*, to fully accomplish its function. Overall, our findings support a synergistic interaction between *Lmo4* and *Fezf2* in subtype-specific functions during the molecular refinement of neocortical subcerebral versus callosal identity. Based on these findings, we propose that subtype-specific TF-directed reprogramming requires epigenetic regulation to improve efficiency and accuracy.

Besides acquiring DL-like molecular identities, our data show that reprogrammed UL neurons can extend their axons to new targets, despite their ectopic location (i.e., location in upper layers). Compared to earlier reports [2, 4], the synergy of *Lmo4* and *Fezf2* allows a more robust axonal rewiring of reprogrammed neurons. Already at embryonic stages, high *Fezf2/Lmo4* expression in UL completely abolishes callosal neurons to cross the midline by rewiring them to subcerebral targets, such as the thalamus and cerebral peduncle, in line with a high number of electroporated cells expressing layers V and VI markers. The reprogrammed molecular signature is largely maintained until P35, except for the layer VI marker *Darpp32* normally expressed in dopaminergic neurons and probably dependent on dopaminergic innervation from the basal ganglia [40, 58].

Moreover, this study shows that the persistent co-expression of *Fezf2* and *Lmo4*

allows a more extended period of postnatal neuronal reprogramming than previously reported with *Fezf2* alone. Induction of *Fezf2/Lmo4* expression at P3 and P7 strongly stimulates the expression of the late layer V marker *Pcp4* together with subcerebral axonal rewiring, particularly towards the cerebral peduncle and spinal cord. Although this ability of rewiring becomes progressively reduced as development proceeds, labeled axons can still be detected in the spinal cord upon *Fezf2/Lmo4* induction at P21. The use of the 'spaghetti monster' fluorescent protein (smFP), which increases the sensitivity in neurons and notably in axons [46], has helped us in labeling rewired axons. Overall, our study shows a synergistic function of *Lmo4* with *Fezf2* in reprogramming callosal projection neurons into corticofugal, and particularly into subcerebral layer V-like neurons (**Fig 8A**). Whether *Lmo4* can enhance the reprogramming capabilities of other TFs in other neurons is still not known but worth investigating further.

**Fig 8. Model of *Fezf2/Lmo4* synergistic reprogramming effect on pyramidal neurons (A) and glial cells (B).** (A) By electroporating (IUE) *Fezf2* and *Lmo4* in upper layer (UL) neurons normally projecting contralaterally either at embryonic E14.5 or postnatally, these neurons acquire a deep layer (DL)-like signature and tend to project outside of the cortex to subcerebral targets, such as the striatum, thalamus, internal capsule, cerebral peduncle and/or spinal cord. This lineage conversion is more efficient in the motor (M1) than in the somatosensory (S1) cortex and at prenatal than at postnatal stages. (B) Injection of a retrovirus either carrying *Neurog2/Bcl2* (NB), *Neurog2/Bcl2* and *Fezf2* (NBF) or *Neurog2/Bcl2* and *Fezf2/Lmo4* (NBFL) into P5 cortical proliferative glial cells leads to increased complexity and a higher proportion of iNs to express the DL layer marker *Ctip2*.

### **Glia-to-neuron reprogramming by *Fezf2* and *Lmo4***

A fundamental question in the field of direct lineage reprogramming is whether cells that underwent fate conversion can acquire fully mature subtype-specific phenotypes [6]. In fact, in many lineage-reprogramming paradigms, cells adopt a hybrid cell state, thereby interfering with the acquisition of full functionality [59]. Thus, it is of utmost importance to develop strategies to resolve such hybrid states which are likely a consequence of incomplete remodeling of the epigenetic landscape of the cell of origin. In this study, after having noted strong DL promoting activity in early and late postmitotic cortical neurons, we examined the effect of co-expressing the terminal selector gene *Fezf2* and the transcriptional adaptor *Lmo4* together with a well-established reprogramming factor cocktail of the proneural gene *Neurog2* and the anti-cell death regulator *Bcl2* [15, 18]. Towards this, we utilized a

reprogramming paradigm that allows for selective targeting of proliferative glia (i.e., approximately 2/3 astroglia and 1/3 oligodendrocyte progenitor cells) in the early postnatal cerebral cortex by retroviruses encoding reprogramming factors [15]. We found that consistent with its role as terminal selector gene during cortical development [51, 53], *Fezf2* enhanced expression of the cortical layer V marker *Ctip2* in neurons induced by *Neurog2/Bcl2* and *Fezf2* alone or in combination with *Lmo4*, which appeared to exert little neurogenic reprogramming activity on its own. This effect was most accentuated in cortical layer V where *Ctip2* neurons are most abundant (**Fig 8B**). These data could point to the intriguing possibility that the local environment exerts significant influence on the molecular maturation of iNs *via* its layer-specific neuronal and glial signaling compartments. Contrary to what we have observed in the neuron-to-neuron reprogramming paradigm, co-expression of *Lmo4* did not overtly enhance the deep layer fate-inducing action of *Fezf2*. However, we noticed increased dendritic complexity of iNs expressing the full reprogramming cocktail (*NBFL*). These data argue that *Fezf2* and *Fezf2/Lmo4* regulate distinct aspects of neuronal subtype identity in iNs. Some targets, e.g., the *Ctip2* gene may be sufficiently accessible in the context of *Neurog2/Bcl2*-mediated reprogramming to become activated by *Fezf2*. In contrast, developing a complex dendritic arborization is likely to be dependent on several molecular players, besides *Fezf2* [50], and hence be more vulnerable to incomplete epigenetic remodeling, therefore requiring extra machinery such as that provided, for example, by *Lmo4*. Finally, our morphological reconstructions could not assess whether iNs would extend axonal projections to subcortical targets such as those observed in the neuron-to-neuron reprogramming paradigm. Forming successful connections with target cells is very likely to be of prime importance for iNs achieving full maturation in terms of molecular identity and physiological properties. While our reprogramming paradigm contributes to deepening our understanding of cell fate boundaries and how these can be overcome, reprogrammed cells likely face unique challenges for incorporation in pre-existing cortical circuits and we are still in a stage where these need to be understood to improve reprogrammed neurons survival and integration. We do need to realize that reprogramming is a challenging process, especially in an unlesioned environment. Overall, our findings presented here provide an important molecular entry point into further tuning glia-to-neuron reprogramming toward generating iNs that resemble endogenous neurons in connectivity and functionality.

### **Limitations of the study**

The findings of this study must be seen in light of some limitations. First, we conducted the analysis of the postnatal glia-to-neuron *in vivo* reprogramming experiment in an unlesioned P5 brain only at 12dpi, based on previous evidence of retrovirus-mediated glia-to-neuron reprogramming and acquisition of neuronal subtype-specific hallmarks within 1-3 weeks [12, 15, 18]. At this early time point, the reprogrammed neurons did not reach a fully mature state, and this is largely reflected in their morphology, which is different from the morphology of endogenous cortical neurons. At this stage, reprogrammed neurons appear smaller in size, with a smaller body size, and no spine-like structures were found. This is consistent with earlier findings of the presence of spine-like structures only from later reprogramming stages, in Neurog2-Bcl2 reprogrammed glia in the adult lesioned cortex [18].

Second, our study is represented by the technical challenges of reliably quantifying axons and tracts upon *in utero* electroporation (IUE). In this study, we prioritized a strong and extensive molecular characterization of our IUE reprogrammed neurons, which required extensive tissue sectioning, 2D immunostaining and high-resolution imaging. However, this limited the power of our tract and axon analysis, which we decided to include solely as a merely qualitative assessment. To better investigate connectivity changes in IUE experiments, a more extensive analysis would be to rely on more advanced technologies (i.e., 3D imaging or spatial alignment to a common 3D reference atlas). However, considering the high number of conditions evaluated in this study (four distinct genetic conditions for five time points) we privileged a high throughput experimental setup for this work, rather than including a comprehensive connectivity analysis, which would instead benefit from being published as a stand-alone study.

## **METHODS**

## Ethics Statement

All experiments were conducted in accordance with the French and German Animal Welfare Act and European guidelines for the use of experimental animals, using protocols approved by the French Ministry of Education, Research and Innovation (reference # APAFIS#I 8019-2018112919027679 v4) and the local ethics committee (CIEPAL NCE/2019–548, Nice), and the Rhineland-Palatinate State Authority (permit number 23 177 07-G-15-1-031). All experiments were conducted on RjHan:NMRI mice or C56Bl6/J mice (retroviral injection experiments) obtained from *Janvier Labs*. Upon *in utero* electroporation only (**Figs 1-5**) or followed by tamoxifen injection (**Figs 4 and 5**) or retroviral injection (**Figs 6 and 7**) both male and female animals were used for the analyses. Female and male RjHan:NMRI or C56Bl6/J mice were put in mating in the evening, and midday of the day of the observed vaginal plug was considered as embryonic day 0.5 (E0.5).

## Plasmids

For embryonic reprogramming at E14.5, the *pCdk5r-Lmo4-IRES-GFP*, *pCdk5r-Fezf2-IRES-GFP* and *pCdk5r-IRES-GFP* plasmids were used. *pCdk5r-Fezf2-IRES-GFP* and *pCdk5r-IRES-GFP* were donated by the lab of Paola Arlotta [2], while *pCdk5r-Lmo4-IRES-GFP* was generated in the lab (Harb *et al.*, 2016). All plasmids were tested for correct expression (**S1 Fig**). To induce the expression of *Lmo4* and *Fezf2* at postnatal stages upon *in utero* electroporation, *Fezf2* and *Lmo4* cDNAs were subcloned into the *pCAG-fl-mutCherry-fl-IRES-EGFP* vector [44] by substituting the *mutCherry* with *Fezf2* or *Lmo4*, resulting in *pCAG-Ind-GFP (iGFP)*, *pCAG-Ind-Fezf2 (iFezf2)* and *pCAG-Ind-Lmo4 (iLmo4)*. The plasmids consist of a *stop* sequence flanked by *loxP* sites in the same directional orientation as the inserted cDNAs and followed by an IRES-GFP sequence to allow EGFP reporter expression. Correct expression of the genes of interest was then elicited *via* a Tamoxifen-dependent Cre recombination (**S3 Fig**). The *pCAG-CreERT2* plasmid is commercially available from *Addgene* (#13777). Since the GFP of the inducible *Lmo4* and *Fezf2* plasmids was not appropriate for following reporter expression into secondary axons and collaterals of electroporated cells, the *pCAG-smFP\_FLAG (Addgene #59756)* was added to the reprogramming factors to facilitate axonal tract tracing (**Figs 5 and S4-S6**).

### ***In utero* electroporation (IUE)**

The experimental procedure for *in utero* electroporation was performed according to the protocol of Saito and Nakatsuji [60] with the following modifications: endotoxin-free plasmids were diluted in TE-Buffer (Qiagen, #1018499) until a cumulative concentration of 1 µg/µl in a final volume of 20 µl, including 1x Fast Green FCF (Sigma-Aldrich, #F7252). Pregnant females of 14.5 days were deeply anesthetized *via* intraperitoneal (i.p.) injection of 250 µl to 350 µl of Tiletamine-Zolazepam-Xylazine-Buprenorphine, shaved on the upper abdomen and cleaned with disinfectant (Pierre Fabre, #716431). After a lateral laparotomy was performed, the uterus was exposed by carefully pulling with ring forceps. Microinjection of the DNA mix was performed using capillaries (Harvard-Apparatus, #30-0016), produced with a micropipette puller (Sutter Instrument, Model P-1000; Parameters: Heat 459, Pull 60, Vel 75, Time/del 100, Pressure 200) and cut open at approximately 60 µm from the tip. The capillaries were inserted into a holder connected to a microinjector (Eppendorf FemtoJet 5274 V2.02; Parameters: Pi[hPA] 100 – 300, ti[s] 0.7, Pc[hPA] 7) and approximately 1 µl of the plasmid mix was injected into one of the two lateral ventricles. To direct the DNA mix to the region of interest, as well as open pores on the cell membrane and facilitate DNA intake, tweezer electrodes (3 mm, Nepagene, #CUY650P3) were placed onto the uterine wall, with the plus node on the premature M1 or S1 area underneath, to apply square electric pulses (Without poring pulse; Transfer pulse Voltage: 37, Pulse length: 50 ms, Pulse interval: 999 ms, Number of pulses: 4, Decay rate: 5%) *via* an electroporator device (Nepagene Superelectroporator, Nepa21 Typell). The uterus was subsequently repositioned into the abdomen and the incision was sewed up with sutures (Péters Surgical; 6/0 #87002F for peritoneum and 5/0 #87001F for skin). 120 µl of the anti-inflammatory Meloxicam (Metacam) and 200 µl of the antibiotic Gentamicin (1 mg/ml, Sigma #G1272) were subcutaneously injected to prevent inflammation. Electroporated mice were then housed in a solitary ventilated black box for 24h after the surgery to recover, before being then transferred to the husbandry room.

### **Tamoxifen injection**

To induce expression of the CRE-recombinase from the *pCAG-CRE-ERT2* plasmid, 4-hydroxy tamoxifen (TAM) was administered at the desired developmental stage. Briefly, 10 ml of 10 mg/ml TAM was prepared by dissolving 100 mg TAM (Sigma, #T5648-1G) in 500 µl Ethanol

absolute in an Eppendorf tube. The solution was stirred on a rotator for 20 min at RT, before diluting it with 9.5 ml of corn oil (Sigma, #C8267). Then, the mix was thoroughly vortexed and put back on a rotator until complete dissolution and 1 ml aliquots were prepared and stored at -20°C until usage. Mice received a single administration of tamoxifen *via* subcutaneous injections under the neck. Injected volumes adapted to their age: P3-P7, 50 µl; P10-P14, 100 µl; P21, 150 µl.

### **Retroviral constructs and retrovirus injections**

Moloney Murine Leukaemia Virus (MMLV)-based retroviral vectors were used for overexpression of the reprogramming factors in the cerebral cortex of postnatal day 5 (P5) mice [49]. The following constructs were used: *CAG-mNeurog2-T2A-hBcl2-IRES-DsRed* [15], *CAG-Fezf2-IRES-eGFP* and *CAG-Fezf2-P2A-Lmo4-IRES-eGFP*, which were cloned by inserting the cDNAs under the control of the chicken  $\beta$ -actin promoter with a cytomegalovirus enhancer (pCAG) and an enhanced green fluorescent protein (GFP) or DsRed reporter cloned behind an Internal Ribosome Entry Site (IRES) to identify transduced cells. Vesicular Stomatitis Virus Glycoprotein (VSV-G)-pseudotyped retroviral particles were produced using gpg helper-free packaging cells [61]. Viral titers used were in the range of  $10^7$  TU/ml, as measured by transduction of HEK293 cells. Retroviral particles were injected into the cerebral cortex of male and female P5 wild-type C57Bl6/J mice kept with their mother purchased from Janvier Labs. Mice were housed in Polycarbonate Type II cages (350 cm<sup>2</sup>) in a 12:12 h light-dark cycle and were provided with food and water *ad libitum*. All efforts were made to reduce the number of animals and their suffering. A subcutaneous injection of Carprofen (Rimadyl, Zoetis, 4 mg/kg of body weight, in 0.9% NaCl [Amresco]) was made prior to the surgery and anaesthesia was induced by i.p. injection of a solution of 0.5 mg/kg Medetomidin (Pfizer), 5 mg/kg Midazolam (Hameln) and 0.025 mg/kg Fentanyl (Albrecht) in 0.9% NaCl. A small skin incision was made above the somatosensory cortex and the skull was minimally opened using a needle. 0.5-1 µl of retroviral suspension was delivered into the cerebral cortex using pulled glass capillaries (20 µm tip diameter, Hirschmann, 9600105). After injection, the capillary was carefully removed, and the wound was closed with surgical glue (3M Vetbond, NC0304169). Animals then received an i.p. injection of a solution of 2.5 mg/kg Atipamezol (Pfizer), 0.5 mg/kg Flumazenil (Hameln) and 0.1 mg/kg Buprenorphin (RB Pharmaceuticals) in 0.9% NaCl.

Pups were kept on a warm plate (37°C) before returning them to their mother and their recovery state was scored daily for a week after the surgery.

### **Histology and immunohistochemistry**

At the planned developmental stage, *IUE* mice were intracardially perfused with phosphate buffer saline (PBS, 15 ml) and varying amounts of 4% paraformaldehyde (PFA, Sigma-Aldrich, #P6148), according to the animal age (15 ml for pups and young animals until P21, 30 ml for adults). Afterwards, the head was cut and dissected. After checking for successfully electroporated brains (GFP-positive) under an epifluorescence microscope, the tissues were post-fixed in 4% PFA for 2h at room temperature (RT). Then, brains were washed one time in PBS and embedded in 4% Select Agar (Sigma-Aldrich, #A5054) in PBS. All brains were cut coronally in 100 µm-thick vibratome sections (Leica VT 1000S; Speed: 7, Frequency 7) and preserved in PBS-Azide (0.05%) until further processing. For immunostaining, floating slices were incubated in 1 ml blocking buffer (10% Goat serum [Life Technologies, #16210064], 3% BSA [Sigma-Andrich, #A3294], 0.03% Triton-X100 [Sigma-Aldrich, #T8787] in PBS 1x) per well overnight (ON) at 4°C, gently rocking. Then, primary antibodies were diluted in 500 µl antibody buffer (3% Goat serum, 3% BSA, 0.03% Triton-X100 in PBS 1x) per well for two days at 4°C. Subsequently, slices were washed three times for 10' at RT and two times for one hour. Secondary antibodies were diluted 1:400 in antibody buffer and 500 µl were added to each well and incubated ON at 4°C. Slices were washed again, as described before, then incubated with 500 µl of DAPI (diluted 1:10000 in PBS - Invitrogen, #H3570) at RT for 5' before mounted on glass microscope slides (Thermo scientific, #J1800AMNZ) with 200 µl of Mowiol mounting medium and enclosed with a cover slip. In the brains electroporated with the *cGFP*, *cFezf2* and *cLmo4* plasmids, the GFP signal was enhanced using an anti-GFP antibody, whereas in the brains electroporated with the *iGFP*, *iFezf2*, *iLmo4* together with the *pCAG-smFP\_FLAG* plasmids, only the anti-FLAG antibody was used to visualize axonal projections (see *Suppl. Table 1 for antibody details*).

Retrovirally injected tissue was processed as follows. After terminal anesthesia with a solution of 120 mg/kg Ketamine (Zoetis) and 16 mg/kg Xylazine (Bayer) (in 0.9% NaCl, i.p.), mice were transcardially perfused with pre-warmed 0.9% NaCl followed by ice-cold 4% paraformaldehyde (PFA, Sigma, P6148). Brains were post-fixed overnight in PFA 4% at 4°C and

sliced coronally (40  $\mu\text{m}$  thick sections) using a vibratome (Microm HM650V, Thermo Scientific). Brain sections were then stored at  $-20^{\circ}\text{C}$  in a cryoprotective solution (20% glucose [Sigma, G8270], 40% ethylene glycol [Sigma, 324558], 0.025% sodium azide [Sigma, S2202], in 0.5 X phosphate buffer [15mM  $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$  [Merck, 10039-32-4]; 16mM  $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$  [Merck, 13472-35-0]; pH 7.4]). For immunohistochemistry, free-floating sections were washed three times for 15 min with 1X TBS (50mM Tris [Invitrogen, 15504-020]; 150 mM NaCl [Amresco, 0241]; pH7.6), incubated for 90 min in blocking solution (5% Donkey Serum [Sigma, S30]; 0.3% Triton X-100; 1X TBS) and then with primary antibodies (diluted in blocking solution) for 2-3 h at room temperature (RT) and overnight at  $4^{\circ}\text{C}$ . After three washes with 1X TBS, slices were incubated with secondary antibodies (diluted blocking solution) for 90 min at RT. Sections were washed twice with 1X TBS, incubated with DAPI (in 1X TBS, Sigma, D8417) for 5-7 min at RT, washed three times with 1X TBS and two times with 1X Phosphate Buffer (30 mM  $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$  [Merck, 10039-32-4]; 33 mM  $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$  [Merck, 13472-35-0]; pH 7.4). Finally, sections were mounted on Superfrost (Thermo Fisher Scientific) microscope slides and covered with coverglasses using Prolong<sup>TM</sup>Gold (Invitrogen, #P36930). For the complete list of primary and secondary antibodies, see Suppl. Table 1.

### **Microscopic imaging and image analysis**

For whole brains and tract tracing imaging, mosaic microscopic images were acquired using an Axio Imager M2 epifluorescence microscope (Carl Zeiss Microscopy GmbH, Jena, Germany) equipped with a halogen lamp, MCU 2008 motorized stage, and an EC Plan-Neofluar 10x/0.30 and an AxioCam MRm camera. ZEN blue software was used for imaging and automatic stitching. For molecular analyses, imaging was performed using a Zeiss 710 confocal microscope equipped with a 405nm diode, an argon ion, a 561nm DPSS and a 647 HeNe lasers. For molecular studies as well as morphological characterization of retrovirus-infected glial cells, Z-stacks of fixed cortical sections were imaged using a LD-LCI Plan-Apo 25x/0.8 NA. Images from immunostaining experiments were analysed by using Fiji-ImageJ Software. Each immunofluorescent slice was carefully checked for the right neocortical area (M1 or S1) and their respective anatomy using Allen Brain Atlas or Atlas of the Developing Mouse Brain (Paxinos et al., 2007, ISBN 0-12-547622-1). Experiments were given random numbers to avoid bias in the analysis. Four layers of confocal images were stacked (2  $\mu\text{m}$  x 4) and the total number of GFP-positive cells counted. Then, markers were screened for co-localization with

GFP-positive cells using orthogonal view for 3D presentation. Then, the sum of double GFP-marker positive cells was divided by the number of total GFP-positive cells to assess the prevalence of each marker on the total GFP population. Serial z-stacks images of retrovirally-transduced tissue sections were acquired with a TCS SP5 (Leica) confocal microscope (Institute of Molecular Biology, Mainz, Germany) equipped with four lasers (405 Diode, Argon, HeNe 543, HeNe 633) using a 20x dry objective (NA 0.7) or a 40x oil objective (NA 1.3), or with an Axio Imager.M2 fluorescent microscope equipped with an ApoTome (Zeiss) using a 20x dry objective (NA 0.7). Analysis of DCX, NeuN and Ctip2 expression in retrovirally-transduced cells was performed in ImageJ using the Cell Counter tool. For calculation of the depth position of the cells relative to the cortical surface, the value of the y-position (depth axis) of the cortical surface was measured with 80  $\mu\text{m}$  intervals along the x-axis (latero-medial axis). Each of these values thereby defined the y-position of the cortical surface at the center of 80  $\mu\text{m}$ -wide virtual horizontal columns. For each cell, the y-position of the cortical surface of containing the virtual column was subtracted to the measured value of the y-position of the cell.

Morphological features of retrovirally-transduced cells were analyzed using IMARIS software. Cell arborization was reconstructed in a semi-automatic manner, *via* the filament tracer module. An automatic length measuring tool was used to calculate the total dendritic length and the basal dendritic length. Primary dendrites (protrusion originating from the soma), branching points, and branching point orders (integer values equivalent to the number of branching points a dendrite undergoes from its somatic origin to the terminal tip) were manually quantified. An automatic detection of Sholl intersections was used to compute Sholl profiles for every individual cell. Sholl intersections were identified as the number of dendrite intersections for concentric spheres of increasing radius and having as a centre the centroid of the cell body. Distance between radii was set at 10  $\mu\text{m}$ .

### **Statistical analysis**

Graphs and statistical analysis have been performed with Graphpad Prism 7. The results of the molecular analyses (**Figs 1-4**) are represented as percentages and error bars were calculated as standard error of the mean (SEM). For comparisons between plasmids, 1-way ANOVA was applied, followed by Tukey post-hoc test. For grouped comparisons between areas and plasmids, 2-way ANOVA followed by Tukey or Sidak post-hoc test was used. For

each experiment, between 3 and 4 sections per brain were imaged in the somatosensory or motor cortex of electroporated brains. Quantification of GFP+ cells expressing a specific combination of markers were averaged for each brain, and then pooled together with other 2 independent brains, each of which had 3 sections. In total, 9 sections (3 per brain) were quantified to generate the data shown in the histograms and Data sets. “n” refers to the number of animals analyzed. Datasets from the morphological characterization of retrovirally-transduced cells (**Fig 7**) were tested for normality (Kolmogorov–Smirnov) or homoscedasticity (Levene test) before performing parametric (Student t-test, 1-way or 2-way ANOVA followed by Bonferroni’s post hoc test) or non-parametric tests (Welch’s unequal variances t-test or Mann–Whitney test) tests used to determine P-values. Retrovirus-injection data are represented as mean ± SD. The number of independent experiments (n) and the number of cells analyzed is indicated in the figure legend. P-values are included in the figure. Graphs and statistical analysis were performed in GraphPad Prism7 and SPSS Statistics 23 V5 (IBM), respectively. Shapiro-Wilk test was used for testing normality of the distribution of the data. For normally distributed data, Levene test was used to test homogeneity of variances and One-Way ANOVA (in the case of equal variances), or Welch-ANOVA (in the case of non-equal variances) followed by a Tukey post-hoc test was used for comparison of means. For non-normally distributed data, the Kruskal-Wallis test by rank was used for comparison of means. All original data are listed in S1 to S6 Data sets.

	Cortex	Corpus callosum	Striatum	Thalamus	Internal capsule	Cerebral peduncle	Spinal cord
<b>E14.5-P7 (Fig. 1)</b>							
<i>cGFP</i>	+++	+++	+	-	-	-	-
<i>cFezf2</i>	+++	++	++	++	++	++	+
<i>cLmo4 &amp; cFezf2</i>	++	-	++	++	++	++	++
<b>E14.5-P7 (Suppl. Fig. 2)</b>							
<i>cGFP</i>	+++	+++	+	-	-	-	-
<i>cLmo4</i>	+++	+++	-	-	-	-	-
<b>TAM P3 - P8 (Fig. 5)</b>							
<i>iGFP</i>	+++	+++	+	+	+	-	-
<i>iFezf2</i>	+++	++	+	+	+	+	+
<i>iLmo4 &amp; iFezf2</i>	+++	+	++	+	++	++	++

TAM P7 - P14 (Suppl. Fig. 4)							
<i>iGFP</i>	+++	+++	-	-	-	-	-
<i>iFezf2</i>	+++	++	-	+	+	+	-
<i>iLmo4 &amp; iFezf2</i>	+++	++	-	+	++	++	+
TAM P10 - P21 (Suppl. Fig. 5)							
<i>iGFP</i>	+++	++	+	-	-	-	-
<i>iFezf2</i>	+++	++	+	-	+	++	-
<i>iLmo4 &amp; iFezf2</i>	+++	++	+	-	++	+	+
TAM P21 - P35 (Suppl. Fig. 6)							
<i>iGFP</i>	+++	++	+	-	+	-	-
<i>iFezf2</i>	+++	++	+	-	+	+	+
<i>iLmo4 &amp; iFezf2</i>	+++	++	+	-	++	++	++

**Table 1. Qualitative assessment of axonal signals in all experimental conditions.** The first column lists the different experimental conditions together with the corresponding figures. The other columns show the intensity levels of the GFP+ or the FLAG+ signals in the specified anatomical structures. Below, the correspondence of the symbols (-, +, ++, +++) and staining levels. The high intensity observed in the cortex (+++) was used as a point of comparison.

## ACKNOWLEDGEMENTS

We would like to thank Qiang Lu and Paola Arlotta for the *Cdk5r-Ctrl GFP* and *Cdk5r-Fezf2-IRES-GFP* plasmids, respectively. We acknowledge support from the Microscopy Core Facility of the Institute of Molecular Biology (IMB) Mainz, and of the iBV PRISM imaging platform.

## REFERENCES :

1. Arlotta P, Berninger B. Brains in metamorphosis: reprogramming cell identity within the central nervous system. *Curr Opin Neurobiol.* 2014;27:208-14. doi: 10.1016/j.conb.2014.04.007. PubMed PMID: 24800935; PubMed Central PMCID: PMC4122594.
2. Rouaux C, Arlotta P. Direct lineage reprogramming of post-mitotic callosal neurons into corticofugal neurons in vivo. *Nat Cell Biol.* 2013;15(2):214-21. Epub 2013/01/22. doi: ncb2660 [pii] 10.1038/ncb2660. PubMed PMID: 23334497.
3. Zuccotti A, Le Magueresse C, Chen M, Neitz A, Monyer H. The transcription factor Fezf2 directs the differentiation of neural stem cells in the subventricular zone toward a cortical phenotype. *Proc Natl Acad Sci U S A.* 2014;111(29):10726-31. Epub 20140707. doi: 10.1073/pnas.1320290111. PubMed PMID: 25002477; PubMed Central PMCID: PMC4115522.

4. De la Rossa A, Bellone C, Golding B, Vitali I, Moss J, Toni N, et al. In vivo reprogramming of circuit connectivity in postmitotic neocortical neurons. *Nat Neurosci.* 2013;16(2):193-200. Epub 2013/01/08. doi: nn.3299 [pii] 10.1038/nn.3299. PubMed PMID: 23292682.
5. Falk S, Han D, Karow M. Cellular identity through the lens of direct lineage reprogramming. *Curr Opin Genet Dev.* 2021;70:97-103. Epub 20210729. doi: 10.1016/j.gde.2021.06.015. PubMed PMID: 34333231.
6. Leaman S, Marichal N, Berninger B. Reprogramming cellular identity in vivo. *Development.* 2022;149(4). Epub 20220223. doi: 10.1242/dev.200433. PubMed PMID: 35195260.
7. Bocchi R, Masserdotti G, Gotz M. Direct neuronal reprogramming: Fast forward from new concepts toward therapeutic approaches. *Neuron.* 2022;110(3):366-93. Epub 20211218. doi: 10.1016/j.neuron.2021.11.023. PubMed PMID: 34921778.
8. Berninger B, Costa MR, Koch U, Schroeder T, Sutor B, Grothe B, et al. Functional properties of neurons derived from in vitro reprogrammed postnatal astroglia. *J Neurosci.* 2007;27(32):8654-64. doi: 10.1523/JNEUROSCI.1615-07.2007. PubMed PMID: 17687043.
9. Heinrich C, Blum R, Gascon S, Masserdotti G, Tripathi P, Sanchez R, et al. Directing astroglia from the cerebral cortex into subtype specific functional neurons. *PLoS Biol.* 2010;8(5):e1000373. doi: 10.1371/journal.pbio.1000373. PubMed PMID: 20502524; PubMed Central PMCID: PMC2872647.
10. Grande A, Sumiyoshi K, Lopez-Juarez A, Howard J, Sakthivel B, Aronow B, et al. Environmental impact on direct neuronal reprogramming in vivo in the adult brain. *Nature communications.* 2013;4:2373. doi: 10.1038/ncomms3373. PubMed PMID: 23974433; PubMed Central PMCID: PMC3786770.
11. Jorstad NL, Wilken MS, Grimes WN, Wohl SG, VandenBosch LS, Yoshimatsu T, et al. Stimulation of functional neuronal regeneration from Muller glia in adult mice. *Nature.* 2017;548(7665):103-7. Epub 20170726. doi: 10.1038/nature23283. PubMed PMID: 28746305; PubMed Central PMCID: PMC5991837.
12. Heinrich C, Bergami M, Gascon S, Lepier A, Vigano F, Dimou L, et al. Sox2-mediated conversion of NG2 glia into induced neurons in the injured adult cerebral cortex. *Stem cell reports.* 2014;3(6):1000-14. Epub 2014/12/03. doi: [S2213-6711\(14\)00329-4 \[pii\] 10.1016/j.stemcr.2014.10.007](https://doi.org/10.1016/j.stemcr.2014.10.007). PubMed PMID: 25458895.
13. Lentini C, d'Orange M, Marichal N, Trottmann MM, Vignoles R, Foucault L, et al. Reprogramming reactive glia into interneurons reduces chronic seizure activity in a mouse model of mesial temporal lobe epilepsy. *Cell Stem Cell.* 2021;28(12):2104-21 e10. Epub 20210929. doi: 10.1016/j.stem.2021.09.002. PubMed PMID: 34592167; PubMed Central PMCID: PMC8657801.
14. Masserdotti G, Gillotin S, Sutor B, Drechsel D, Irmler M, Jorgensen HF, et al. Transcriptional Mechanisms of Proneural Factors and REST in Regulating Neuronal Reprogramming of Astrocytes. *Cell Stem Cell.* 2015;17(1):74-88. doi: 10.1016/j.stem.2015.05.014. PubMed PMID: 26119235; PubMed Central PMCID: PMC4509553.
15. Herrero-Navarro A, Puche-Aroca L, Moreno-Juan V, Sempere-Ferrandez A, Espinosa A, Susin R, et al. Astrocytes and neurons share region-specific transcriptional signatures that confer regional identity to neuronal reprogramming. *Sci Adv.* 2021;7(15). Epub 20210407. doi: 10.1126/sciadv.abe8978. PubMed PMID: 33827819; PubMed Central PMCID: PMC8026135.
16. Kempf J, Knelles K, Hersbach BA, Petrik D, Riedemann T, Bednarova V, et al. Heterogeneity of neurons reprogrammed from spinal cord astrocytes by the proneural factors Ascl1 and Neurogenin2. *Cell reports.* 2021;36(7):109571. doi: 10.1016/j.celrep.2021.109571. PubMed PMID: 34407409; PubMed Central PMCID: PMC8386286.
17. Liu ML, Zang T, Zou Y, Chang JC, Gibson JR, Huber KM, et al. Small molecules enable neurogenin 2 to efficiently convert human fibroblasts into cholinergic neurons. *Nature communications.* 2013;4:2183. doi: 10.1038/ncomms3183. PubMed PMID: 23873306; PubMed Central PMCID: PMC3843951.

18. Gascon S, Murenu E, Masserdotti G, Ortega F, Russo GL, Petrik D, et al. Identification and Successful Negotiation of a Metabolic Checkpoint in Direct Neuronal Reprogramming. *Cell Stem Cell*. 2016;18(3):396-409. doi: 10.1016/j.stem.2015.12.003. PubMed PMID: 26748418.
19. Russo GL, Sonsalla G, Natarajan P, Breunig CT, Bulli G, Merl-Pham J, et al. CRISPR-Mediated Induction of Neuron-Enriched Mitochondrial Proteins Boosts Direct Glia-to-Neuron Conversion. *Cell Stem Cell*. 2021;28(3):584. doi: 10.1016/j.stem.2020.11.017. PubMed PMID: 33667363; PubMed Central PMCID: PMC7939519.
20. Chen B, Schaevitz LR, McConnell SK. Fezl regulates the differentiation and axon targeting of layer 5 subcortical projection neurons in cerebral cortex. *Proc Natl Acad Sci U S A*. 2005;102(47):17184-9. PubMed PMID: 16284245.
21. Chen B, Wang SS, Hattox AM, Rayburn H, Nelson SB, McConnell SK. The Fezf2-Ctip2 genetic pathway regulates the fate choice of subcortical projection neurons in the developing cerebral cortex. *Proc Natl Acad Sci U S A*. 2008;105(32):11382-7. PubMed PMID: 18678899.
22. Lodato S, Shetty AS, Arlotta P. Cerebral cortex assembly: generating and reprogramming projection neuron diversity. *Trends Neurosci*. 2015;38(2):117-25. doi: 10.1016/j.tins.2014.11.003. PubMed PMID: 25529141; PubMed Central PMCID: PMC4334136.
23. Xu J, Du Y, Deng H. Direct lineage reprogramming: strategies, mechanisms, and applications. *Cell Stem Cell*. 2015;16(2):119-34. doi: 10.1016/j.stem.2015.01.013. PubMed PMID: 25658369.
24. Morris SA. Direct lineage reprogramming via pioneer factors; a detour through developmental gene regulatory networks. *Development*. 2016;143(15):2696-705. doi: 10.1242/dev.138263. PubMed PMID: 27486230; PubMed Central PMCID: PMC45004913.
25. Wapinski OL, Vierbuchen T, Qu K, Lee QY, Chanda S, Fuentes DR, et al. Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. *Cell*. 2013;155(3):621-35. Epub 20131024. doi: 10.1016/j.cell.2013.09.028. PubMed PMID: 24243019; PubMed Central PMCID: PMC3871197.
26. Lerner J, Gomez-Garcia PA, McCarthy RL, Liu Z, Lakadamyali M, Zaret KS. Two-Parameter Mobility Assessments Discriminate Diverse Regulatory Factor Behaviors in Chromatin. *Mol Cell*. 2020;79(4):677-88 e6. Epub 20200622. doi: 10.1016/j.molcel.2020.05.036. PubMed PMID: 32574554; PubMed Central PMCID: PMC7483934.
27. Wang N, Lin KK, Lu Z, Lam KS, Newton R, Xu X, et al. The LIM-only factor LMO4 regulates expression of the BMP7 gene through an HDAC2-dependent mechanism, and controls cell proliferation and apoptosis of mammary epithelial cells. *Oncogene*. 2007;26(44):6431-41. doi: 10.1038/sj.onc.1210465. PubMed PMID: 17452977.
28. Azim E, Shnider SJ, Cederquist GY, Sohur US, Macklis JD. Lmo4 and Clim1 progressively delineate cortical projection neuron subtypes during development. *Cereb Cortex*. 2009;19 Suppl 1:i62-9. Epub 2009/04/16. doi: bhp030 [pii] 10.1093/cercor/bhp030. PubMed PMID: 19366868; PubMed Central PMCID: PMC2693532.
29. Cederquist GY, Azim E, Shnider SJ, Padmanabhan H, Macklis JD. Lmo4 establishes rostral motor cortex projection neuron subtype diversity. *J Neurosci*. 2013;33(15):6321-32. doi: 10.1523/JNEUROSCI.5140-12.2013. PubMed PMID: 23575831; PubMed Central PMCID: PMC3698850.
30. Sang M, Ma L, Sang M, Zhou X, Gao W, Geng C. LIM-domain-only proteins: multifunctional nuclear transcription coregulators that interacts with diverse proteins. *Molecular biology reports*. 2014;41(2):1067-73. doi: 10.1007/s11033-013-2952-1. PubMed PMID: 24379077.
31. Harb K, Magrinelli E, Nicolas CS, Lukianets N, Frangeul L, Pietri M, et al. Area-specific development of distinct projection neuron subclasses is regulated by postnatal epigenetic modifications. *eLife*. 2016;5. doi: 10.7554/eLife.09531. PubMed PMID: 26814051.
32. Rouaux C, Arlotta P. Fezf2 directs the differentiation of corticofugal neurons from striatal progenitors in vivo. *Nat Neurosci*. 2010;13(11):1345-7. doi: 10.1038/nn.2658. PubMed PMID: 20953195; PubMed Central PMCID: PMC4207442.

33. Wang X, Qiu R, Tsark W, Lu Q. Rapid promoter analysis in developing mouse brain and genetic labeling of young neurons by doublecortin-DsRed-express. *J Neurosci Res.* 2007;85(16):3567-73. doi: 10.1002/jnr.21440. PubMed PMID: 17671991.
34. Delalle I, Bhide PG, Caviness VS, Jr., Tsai LH. Temporal and spatial patterns of expression of p35, a regulatory subunit of cyclin-dependent kinase 5, in the nervous system of the mouse. *J Neurocytol.* 1997;26(5):283-96. doi: 10.1023/a:1018500617374. PubMed PMID: 9192293.
35. Rodriguez-Tornos FM, Briz CG, Weiss LA, Sebastian-Serrano A, Ares S, Navarrete M, et al. Cux1 Enables Interhemispheric Connections of Layer II/III Neurons by Regulating Kv1-Dependent Firing. *Neuron.* 2016;89(3):494-506. doi: 10.1016/j.neuron.2015.12.020. PubMed PMID: 26804994.
36. Arlotta P, Molyneaux BJ, Chen J, Inoue J, Kominami R, Macklis JD. Neuronal subtype-specific genes that control corticospinal motor neuron development in vivo. *Neuron.* 2005;45(2):207-21. PubMed PMID: 15664173.
37. Watakabe A, Hirokawa J, Ichinohe N, Ohsawa S, Kaneko T, Rockland KS, et al. Area-specific substratification of deep layer neurons in the rat cortex. *J Comp Neurol.* 2012;520(16):3553-73. doi: 10.1002/cne.23160. PubMed PMID: 22678985.
38. Galazo MJ, Emsley JG, Macklis JD. Corticothalamic Projection Neuron Development beyond Subtype Specification: Fog2 and Intersectional Controls Regulate Intraclass Neuronal Diversity. *Neuron.* 2016;91(1):90-106. doi: 10.1016/j.neuron.2016.05.024. PubMed PMID: 27321927; PubMed Central PMCID: PMC5094453.
39. Kwan KY, Lam MM, Krsnik Z, Kawasawa YI, Lefebvre V, Sestan N. SOX5 postmitotically regulates migration, postmigratory differentiation, and projections of subplate and deep-layer neocortical neurons. *Proc Natl Acad Sci U S A.* 2008;105(41):16021-6. Epub 2008/10/09. doi: 0806791105 [pii] 10.1073/pnas.0806791105. PubMed PMID: 18840685; PubMed Central PMCID: PMC2572944.
40. Ouimet CC, Miller PE, Hemmings HC, Jr., Walaas SI, Greengard P. DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. *J Neurosci.* 1984;4(1):111-24. PubMed PMID: 6319625.
41. Harris KD, Shepherd GM. The neocortical circuit: themes and variations. *Nat Neurosci.* 2015;18(2):170-81. doi: 10.1038/nn.3917. PubMed PMID: 25622573.
42. Tomassy GS, De Leonibus E, Jabaudon D, Lodato S, Alfano C, Mele A, et al. Area-specific temporal control of corticospinal motor neuron differentiation by COUP-TFI. *Proc Natl Acad Sci U S A.* 2010;107(8):3576-81. Epub 2010/02/06. doi: 0911792107 [pii] 10.1073/pnas.0911792107. PubMed PMID: 20133588; PubMed Central PMCID: PMC2840488.
43. Molyneaux BJ, Arlotta P, Hirata T, Hibi M, Macklis JD. Fezl is required for the birth and specification of corticospinal motor neurons. *Neuron.* 2005;47(6):817-31. PubMed PMID: 16157277.
44. Yan K, Bormuth I, Bormuth O, Tutukova S, Renner A, Bessa P, et al. TrkB-dependent EphrinA reverse signaling regulates callosal axon fasciculate growth downstream of Neurod2/6. *Cereb Cortex.* 2022. Epub 20220423. doi: 10.1093/cercor/bhac170. PubMed PMID: 35462405.
45. Matsuda T, Cepko CL. Controlled expression of transgenes introduced by in vivo electroporation. *Proc Natl Acad Sci U S A.* 2007;104(3):1027-32. Epub 20070105. doi: 10.1073/pnas.0610155104. PubMed PMID: 17209010; PubMed Central PMCID: PMCPMC1764220.
46. Viswanathan S, Williams ME, Bloss EB, Stasevich TJ, Speer CM, Nern A, et al. High-performance probes for light and electron microscopy. *Nature methods.* 2015;12(6):568-76. doi: 10.1038/nmeth.3365. PubMed PMID: 25915120; PubMed Central PMCID: PMC4573404.
47. Roe T, Reynolds TC, Yu G, Brown PO. Integration of murine leukemia virus DNA depends on mitosis. *EMBO J.* 1993;12(5):2099-108. doi: 10.1002/j.1460-2075.1993.tb05858.x. PubMed PMID: 8491198; PubMed Central PMCID: PMCPMC413431.
48. Ge WP, Miyawaki A, Gage FH, Jan YN, Jan LY. Local generation of glia is a major astrocyte source in postnatal cortex. *Nature.* 2012;484(7394):376-80. Epub 20120328. doi: 10.1038/nature10959. PubMed PMID: 22456708; PubMed Central PMCID: PMCPMC3777276.

49. Galante C, Marichal N, Scarante FF, Ghayad LM, Shi Y, Schuurmans C, et al. Enhanced proliferation of oligodendrocyte progenitor cells following retrovirus mediated Achaete-scute complex-like 1 overexpression in the postnatal cerebral cortex in vivo. *Front Neurosci.* 2022;16:919462. Epub 20221202. doi: 10.3389/fnins.2022.919462. PubMed PMID: 36532282; PubMed Central PMCID: PMCPMC9755855.
50. Chen JG, Rasin MR, Kwan KY, Sestan N. Zfp312 is required for subcortical axonal projections and dendritic morphology of deep-layer pyramidal neurons of the cerebral cortex. *Proc Natl Acad Sci U S A.* 2005;102(49):17792-7. Epub 20051128. doi: 10.1073/pnas.0509032102. PubMed PMID: 16314561; PubMed Central PMCID: PMCPMC1308928.
51. Tsyporin J, Tastad D, Ma X, Nehme A, Finn T, Huebner L, et al. Transcriptional repression by FEZF2 restricts alternative identities of cortical projection neurons. *Cell reports.* 2021;35(12):109269. doi: 10.1016/j.celrep.2021.109269. PubMed PMID: 34161768; PubMed Central PMCID: PMCPMC8327856.
52. Wang H, Yang Y, Liu J, Qian L. Direct cell reprogramming: approaches, mechanisms and progress. *Nature reviews Molecular cell biology.* 2021;22(6):410-24. Epub 20210222. doi: 10.1038/s41580-021-00335-z. PubMed PMID: 33619373; PubMed Central PMCID: PMCPMC8161510.
53. Lodato S, Molyneaux BJ, Zuccaro E, Goff LA, Chen HH, Yuan W, et al. Gene co-regulation by Fezf2 selects neurotransmitter identity and connectivity of corticospinal neurons. *Nat Neurosci.* 2014;17(8):1046-54. doi: 10.1038/nn.3757. PubMed PMID: 24997765; PubMed Central PMCID: PMC4188416.
54. Lattke M, Goldstone R, Ellis JK, Boeing S, Jurado-Arjona J, Marichal N, et al. Extensive transcriptional and chromatin changes underlie astrocyte maturation in vivo and in culture. *Nature communications.* 2021;12(1):4335. Epub 20210715. doi: 10.1038/s41467-021-24624-5. PubMed PMID: 34267208; PubMed Central PMCID: PMCPMC8282848.
55. Alcamo EA, Chirivella L, Dautzenberg M, Dobрева G, Farinas I, Grosschedl R, et al. Satb2 regulates callosal projection neuron identity in the developing cerebral cortex. *Neuron.* 2008;57(3):364-77. PubMed PMID: 18255030.
56. Baranek C, Dittrich M, Parthasarathy S, Bonnon CG, Britanova O, Lanshakov D, et al. Protooncogene Ski cooperates with the chromatin-remodeling factor Satb2 in specifying callosal neurons. *Proc Natl Acad Sci U S A.* 2012;109(9):3546-51. Epub 2012/02/16. doi: 1108718109 [pii] 10.1073/pnas.1108718109. PubMed PMID: 22334647; PubMed Central PMCID: PMC3295291.
57. Britanova O, de Juan Romero C, Cheung A, Kwan KY, Schwark M, Gyorgy A, et al. Satb2 is a postmitotic determinant for upper-layer neuron specification in the neocortex. *Neuron.* 2008;57(3):378-92. PubMed PMID: 18255031.
58. Girault JA, Nairn AC. DARPP-32 40 years later. *Adv Pharmacol.* 2021;90:67-87. Epub 20201202. doi: 10.1016/bs.apha.2020.09.004. PubMed PMID: 33706939.
59. Kong W, Fu YC, Holloway EM, Garipler G, Yang X, Mazzoni EO, et al. Cappybara: A computational tool to measure cell identity and fate transitions. *Cell Stem Cell.* 2022;29(4):635-49 e11. Epub 20220329. doi: 10.1016/j.stem.2022.03.001. PubMed PMID: 35354062; PubMed Central PMCID: PMCPMC9040453.
60. Saito T, Nakatsuji N. Efficient gene transfer into the embryonic mouse brain using in vivo electroporation. *Dev Biol.* 2001;240(1):237-46. doi: 10.1006/dbio.2001.0439. PubMed PMID: 11784059.
61. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. *Proc Natl Acad Sci U S A.* 1996;93(21):11400-6. doi: 10.1073/pnas.93.21.11400. PubMed PMID: 8876147; PubMed Central PMCID: PMCPMC38069.

## SUPPORTING INFORMATION LEGENDS

**S1 Fig: cFezf2 and cLmo4 are properly expressed in GFP+ electroporated cells.** (A) Schematic representation of the experimental design. cLmo4 (cL) and/or cFezf2 (cF) plasmids were electroporated into E14.5 somatosensory (S1) embryonic cortices. Brains were collected at P7. (B) Validation of the correct expression of Fezf2 and Lmo4 proteins by immunofluorescence of electroporated GFP+ cells. Note that almost 90% of GFP+ cells do express Lmo4 and Fezf2 (arrowheads point to triple positive, arrows to single or double positive cells). (C) Double staining of layers V and VI markers with Ctip2, a well-described layer V marker in the somatosensory (S1) cortex of WT brains. Percentages shown as mean  $\pm$  s.e.m. indicate the degree of co-localization of Fog2, Pcp4 and Darpp32 with high or low expression of Ctip2 in layers V and VI. All individual data are listed in S1 Data.

**S2 Fig: Overexpression of cLmo4 fails to lead to any lineage conversion and axonal rewiring.** (A) Schematic representation of the experimental procedure and vectors. cGFP and cLmo4 (cL) plasmids were electroporated into E14.5 somatosensory (S1) embryonic cortices. Brains were collected at P7. (B) Immunofluorescence (IF) of GFP on a coronal slice of an electroporated brain confirms the expected laminar localization (layers II-IV) of electroporated GFP+ cells. (C) Percentage of S1 electroporated UL neurons expressing upper versus deep-layer markers. (D) Representative images of Cux1, Ctip2, Fog2, Pcp4 and Darpp32 IF staining in electroporated brains. Full and empty arrowheads respectively indicate whether GFP+ cell co-express or not, respectively, the marker. (E) Tract tracing of upper layer GFP+ axons upon electroporation of cGFP and cLmo4 in P7 brains. No particular changes between cGFP- and cLmo4-electroporated brains have been detected. Scale bars: B= 1000 $\mu$ m (left, macro image) and 200 $\mu$ m (right, magnified image); D= 20 $\mu$ m; E= 1000 $\mu$ m (top row, macro images), 200 $\mu$ m (magnified images). Results are expressed as mean  $\pm$  s.e.m. Two-way ANOVA with Tukey's post-hoc correction was used for statistical analysis, \*\*p<0.01 \*\*\*p<0.0001. n = 3 brains for each plasmid. Abbreviations: CC, corpus callosum; CP, cerebral peduncle; IC, internal capsule; SC, spinal cord; Str, striatum; Th, thalamus. All individual data and statistics are listed in S1 Data. See also Table 1.

**S3 Fig: iFezf2 and iLmo4 are properly expressed in induced electroporated brains.** (A) Schematic representation of the experimental procedure and vectors used in this experiment. iFezf2 (iF) and iLmo4 (iL) were electroporated into E14.5 somatosensory (S1) cortices. Gene expression was induced at P3 by tamoxifen (TAM) subcutaneous injection. Brains were collected at P8. (B) Immunofluorescence (IF) of GFP, upper layer marker Cux1 and deep layer V marker Ctip2 on a coronal slice of an electroporated brain. White box indicates magnification image on the right side. (C) Validation of the correct expression of Fezf2 and Lmo4 proteins by IF of TAM-induced brains. Note that almost all GFP+ cells express Lmo4 and/or Fezf2. Below, confocal images of high-magnification panels showing three-dimensional reconstructions of double staining. Side bars represent projections along the x-z axes (right) and the y-z axes (below). (D) No GFP expression is detected in NO-TAM-induced brains co-electroporated with mCherry (in red). Scale bars: B= 1000 $\mu$ m (left, macro image) and 200 $\mu$ m (right, magnified image); C, D= 20 $\mu$ m.

**S4 Fig: P7 induction of Fezf2 and Lmo4 expression can partially change upper-layer axonal projections toward subcerebral targets.** (A) Schematic representation of the experimental procedure and vectors. iGFP, iFezf2 (iF) or iFezf2 and iLmo4 (iF+iL) together with pCAG-CRE-ERT2 were

electroporated into E14.5 somatosensory (S1) cortices. smFP-Flag reporter plasmid was co-electroporated to facilitate axon tracing. Gene expression was induced at P7 by tamoxifen subcutaneous injection. Brains were collected at P14. **(B)** Tract tracing of upper layer FLAG+ axons upon electroporation of iGFP, iF or iF+iL vectors. Full and empty arrows indicate presence or absence of axons, respectively. FLAG+ axons were found crossing the corpus callosum (CC) in all conditions, but they reached the thalamus (Th), internal capsule (IC), and cerebral peduncle (CP) only in iF and iF+iL conditions; axons were clearly detected in the spinal cord (SC) of iF+iL brains. White boxes indicate regions magnified in the panels below or aside. Scale bars: B = 1000 $\mu$ m (macro images) and 20 $\mu$ m (magnification images). n = 3 brains for each plasmid. Abbreviations: Str, striatum. See also Table 1.

**S5 Fig: P10 induction of double Fe Fezf2 and Lmo4 expression can partially change upper-layer axonal projections toward subcerebral targets.** **(A)** Schematic representation of the experimental procedure and vectors. iGFP, iFezf2 (iF) or iFezf2 and iLmo4 (iF+iL) together with pCAG-CRE-ERT2 were electroporated into E14.5 somatosensory (S1) cortices. smFP-Flag reporter plasmid was co-electroporated to facilitate axon tracing. Gene expression was induced at P10 by tamoxifen subcutaneous injection. Brains were collected at P21. **(B)** Tract tracing of upper layer FLAG+ axons upon electroporation of iGFP, iF or iF+iL vectors. Full and empty arrows indicate the presence or absence of FLAG+ axons, respectively. Axons were found crossing the corpus callosum (CC) and reaching the striatum (Str) in all conditions, but their presence was detected in the internal capsule (IC) and cerebral peduncle (CP) only in iF- and iF+iL-electroporated brains. Although big bundles of axons can be observed in the CP of iF-electroporated brains, no obvious projections seem to reach the spinal cord (SC), differently from iF+iL-electroporated brains in which few dispersed axons ultimately reach the SC. White boxes indicate regions magnified in the panels below or aside. Scale bars: B = 1000 $\mu$ m (macro images) and 20 $\mu$ m (magnification images). n = 3 brains for each plasmid. See also Table 1.

**S6 Fig: P21 induction of single Fezf2 and double Fezf2 and Lmo4 expression can still partially change upper layer axonal projections toward subcerebral targets.** **(A)** Schematic representation of the experimental procedure and vectors. iGFP, iFezf2 (iF) or iFezf2 and iLmo4 (iF+iL) together with pCAG-CRE-ERT2 were electroporated into E14.5 somatosensory (S1) cortices. smFP-Flag reporter plasmid was co-electroporated to facilitate axon tracing. Gene expression was induced at P21 by tamoxifen subcutaneous injection. Brains were collected at P35. **(B)** Tract tracing of upper layer FLAG+ axons upon electroporation of iGFP, iF, or iF+iL vectors. Full and empty arrows indicate the presence or absence of FLAG+ axons, respectively. Axons were found crossing the corpus callosum (CC) and reaching the striatum (Str) and internal capsule (IC) in all conditions. However, labeled axons were only detected in the cerebral peduncle (CP) and spinal cord (SC) of iF- and iF+iL-electroporated brains. White boxes indicate regions magnified in the panels below or aside. Scale bars: B = 1000 $\mu$ m (macro images) and 20 $\mu$ m (magnification images). n = 3 brains for each plasmid. See also Table 1.

**S7 Fig: NBF and NBFL induce glia-to-neuron reprogramming in all cortical layers.** **(A)** Analysis at 12dpi of DCX-expression in NBF- and NBFL-cells with regards to their depth position (relative to the cortical surface) shows that reprogramming is induced at similar rates in all cortical layers. Apparent local accumulation of iNs in the first 200 $\mu$ m below the cortical surface reflects higher numbers of transduced cells at this depth, but not a difference in the reprogramming efficiency (i.e., percentage of DCX-expressing cells among transduced cells). In the graphs, each dot represents a cell. n=3

*brains/retrovirus combination, 2827 cells analyzed. Images illustrate cell distribution in the cortex from the surface to deep layers. All individual data are listed in S5 Data.*

**S1 Data.** *Summary of statistical analysis and results illustrated in Figs 1 and S2C. Highlighted in blue, comparisons that produced statistically significant P-values.*

**S2 Data.** *Summary of statistical analysis and results illustrated in Fig 2. Highlighted in blue, comparisons that produced statistically significant P-values.*


**S3 Data.** *Summary of statistical analysis and results illustrated in Fig 3. Highlighted in blue, comparisons that produced statistically significant P-values.*

**S4 Data.** *Summary of statistical analysis and results illustrated in Fig 4. Highlighted in blue, comparisons that produced statistically significant P-values.*


**S5 Data.** *Summary of statistical analysis and results illustrated in Fig 6. Highlighted in blue, comparisons that produced statistically significant P-values.*

**S6 Data.** *Summary of statistical analysis and results illustrated in Fig 7. Highlighted in blue, comparisons that produced statistically significant P-values.*

**S1 Table.** *Complete list of antibodies used in this study.*




**S1 Fig: *cFefz2* and *cLmo4* are properly expressed in GFP<sup>+</sup> electroporated cells. (A) Schematic representation of the experimental design. *cLmo4* (cL) and *cFefz2* (cF) plasmids were electroporated into E14.5 somatosensory (S1) embryonic cortices. Brains were collected at P7. (B) Validation of the correct expression of *Fefz2* and *Lmo4* proteins by immunofluorescence of electroporated GFP<sup>+</sup> cells. Note that almost all GFP<sup>+</sup> cells do express *Lmo4* and *Fefz2* (arrowheads point to triple-positive, arrows to single or double-positive cells). (C) Double staining of layers V and VI markers with *Ctip2*, a well-described layer V marker in the somatosensory (S1) cortex of WT brains. Percentages shown as mean ± s.e.m. indicate the degree of co-localization of *Fog2*, *Pcp4* and *Darpp32* with high or low expression of *Ctip2* in layers V and VI. All individual data are listed in S1 Data.**





**S2 Fig: Overexpression of cLmo4 fails to lead to any lineage conversion and axonal rewiring.** (A) Schematic representation of the experimental procedure and vectors. cGFP and cLmo4 (cL) plasmids were electroporated



into E14.5 somatosensory (S1) cortices. Brains were collected at P7. **(B)** Immunofluorescence (IF) of GFP on a coronal slice of an electroporated brain confirms the expected laminar localization (layers II-IV) of electroporated GFP+ cells. **(C)** Percentage of S1 electroporated UL neurons expressing upper versus deep-layer markers. **(D)** Representative images of Cux1, Ctip2, Fog2, Pcp4 and Darpp32 IF staining in electroporated brains. Full and empty arrowheads respectively indicate whether GFP+ cells co-express or not, respectively, the marker. **(E)** Tract tracing of upper layer GFP+ axons upon electroporation of cGFP and cLmo4 in P7 brains. No particular changes between cGFP- and cLmo4-electroporated brains have been detected. Scale bars: B= 1000 $\mu$ m (left, macro image) and 200 $\mu$ m (right, magnified image); D= 20 $\mu$ m; E= 1000 $\mu$ m (top row, macro images), 200 $\mu$ m (magnified images). Results are expressed as mean  $\pm$  s.e.m. Two-way ANOVA with Tukey's post-hoc correction was used for statistical analysis, \*\* $p$ <0.01 \*\*\* $p$ <0.0001.  $n$  = 3 brains for each plasmid. Abbreviations: CC, corpus callosum; CP, cerebral peduncle; IC, internal capsule; SC, spinal cord; Str, striatum; Th, thalamus. All individual data and statistics are listed in S1 Data. See also Table 1.




**S3 Fig: *iFezf2* and *iLmo4* are properly expressed in induced electroporated brains.** (A) Schematic representation of the experimental procedure and vectors used in this experiment. *iFezf2* (iF) and *iLmo4* (iL) were electroporated into E14.5 somatosensory (S1) cortices. Gene expression was induced at P3 by tamoxifen (TAM) subcutaneous injection. Brains were collected at P8. (B) Immunofluorescence (IF) of GFP, upper layer marker *Cux1*, and deep layer V marker *Ctip2* on a coronal slice of an electroporated brain. White box indicates the magnification image on the right side. (C) Validation of the correct expression of *Fezf2* and *Lmo4* proteins by IF of TAM-induced brains. Note that almost all GFP<sup>+</sup> cells express *Lmo4* and/or *Fezf2*. Below, confocal images of high-magnification panels showing three-dimensional reconstructions of double staining. Sidebars represent projections along the x-z axes (right) and the y-z axes (below). (D) No GFP expression is detected in NO-TAM-induced brains co-electroporated with *mCherry* (in red). Scale bars: B= 1000 $\mu$ m (left, macro image) and 200 $\mu$ m (right, magnified image); C, D= 20 $\mu$ m.




**Fig S4. P7 induction of *Fezf2* and *Lmo4* expression can partially change upper-layer axonal projections toward subcerebral targets.** (A) Schematic representation of the experimental procedure and vectors. *iGFP*, *iFezf2* (*iF*) or *iFezf2* + *iLmo4* (*iF+iL*) together with pCAG-CRE-ERT2 were electroporated into E14.5 somatosensory (S1) cortices. smFP-Flag reporter plasmid was co-electroporated to facilitate axon tracing. Gene expression was induced at P7 by tamoxifen subcutaneous injection. Brains were collected at P14. (B) Tract tracing of upper layer FLAG+ axons upon electroporation of *iGFP*, *iF* or *iF+iL* vectors. Full and empty arrows indicate the presence or absence of axons, respectively. FLAG+ axons were found crossing the corpus callosum (CC) in all conditions, but they reached the thalamus (Th), internal capsule (IC), and cerebral peduncle (CP) only in *iF* and *iF+iL* conditions; axons were clearly detected in the spinal cord (SC) of *iF+iL* brains. White boxes indicate regions magnified in the panels below or aside. Scale bars: B = 1000 $\mu$ m (macro images) and 20 $\mu$ m (magnification images). n = 3 brains for each plasmid. Abbreviations: Str, striatum. See also Table 1.



**S5 Fig: P10 induction of double *Fezf2* and *Lmo4* expression can partially change upper-layer axonal projections toward subcerebral targets.** (A) Schematic representation of the experimental procedure and vectors. iGFP, iFezf2 (iF), or iFezf2 + iLmo4 (iF+iL) together with pCAG-CRE-ERT2 were electroporated into E14.5 somatosensory (S1) cortices. smFP-Flag reporter plasmid was co-electroporated to facilitate axon tracing. Gene expression was induced at P10 by tamoxifen subcutaneous injection. Brains were collected at P21. (B) Tract tracing of upper layer FLAG+ axons upon electroporation of iGFP, iF, or iF+iL vectors. Full and empty arrows indicate the presence or absence of FLAG+ axons, respectively. Axons were found crossing the corpus callosum (CC) and reaching the striatum (Str) in all conditions, but their presence was detected in the internal capsule (IC) and cerebral peduncle (CP) only in iF- and iF+iL-electroporated brains. Although big bundles of axons can be observed in the CP of iF-electroporated brains, no obvious projections seem to reach the spinal cord (SC), differently from iF+iL-electroporated brains in which few dispersed axons can ultimately reach the SC. White boxes indicate regions magnified in the panels below or aside. Scale bars: B = 1000 $\mu$ m (macro images) and 20 $\mu$ m (magnification images). n = 3 brains for each plasmid. See also Table 1.



**S6 Fig: P21 induction of single *Fezf2* and double *Fezf2* and *Lmo4* expression can still partially change upper-layer axonal projections toward subcerebral targets.** (A) Schematic representation of the experimental procedure and vectors. *iGFP*, *iFefz2* (*iF*) or *iFefz2* and *iLmo4* (*iF+iL*) together with *pCAG-CRE-ERT2* were electroporated into E14.5 somatosensory (*S1*) cortices. *smFP-Flag* reporter plasmid was co-electroporated to facilitate axon tracing. Gene expression was induced at P21 by tamoxifen subcutaneous injection. Brains were collected at P35. (B) Tract tracing of upper layer *FLAG*<sup>+</sup> axons upon electroporation of *iGFP*, *iF*, or *iF+iL* vectors. Full and empty arrows indicate the presence or absence of *FLAG*<sup>+</sup> axons, respectively. Axons were found crossing the corpus callosum (*CC*) and reaching the striatum (*Str*) and internal capsule (*IC*) in all conditions. However, labeled axons were only detected in the cerebral peduncle (*CP*) and spinal cord (*SC*) of *iF*- and *iF+iL*-electroporated brains. White boxes indicate regions magnified in the panels below or aside. Scale bars: *B* = 1000 $\mu$ m (macro images) and 20 $\mu$ m (magnification images). *n* = 3 brains for each plasmid. See also Table 1.



**S7 Fig: NBF and NBFL induce glia-to-neuron reprogramming in all cortical layers.** (A) Analysis at 12dpi of DCX-expression in NBF- and NBFL-cells with regards to their depth position (relative to the cortical surface) shows that reprogramming is induced at similar rates in all cortical layers. Apparent local accumulation of iNs in the first 200 $\mu$ m below the cortical surface reflects higher numbers of transduced cells at this depth, but not a difference in the reprogramming efficiency (i.e., percentage of DCX-expressing cells among transduced cells). In the graphs, each dot represents a cell. n=3 brains/retrovirus combination, 2827 cells analyzed. Images illustrate cell distribution in the cortex from the surface to deep layers. All individual data are listed in S5 Data.

Antigen	Provider	Reference	Host	Use	Working Dilution
GFP	Abcam	ab13970	Chicken	IF – 1AB	1:500
GFP	AvesLab	GFP-1020	Chicken	IF – 1AB	1:1000
Flag	Novusbio	NBP1-0671255	Rat	IF – 1AB	1:200
Cux1	Merk-Millipore	ABE217	Rabbit	IF – 1AB	1:200
Ctip2	Abcam	ab18465	Rat	IF – 1AB	1:500
Fog2	Santa Cruz	sc-10755	Rabbit	IF – 1AB	1:200
PCP4	Thermo Fisher	PA5-52209	Rabbit	IF – 1AB	1:200
Darp32	Abcam	ab40801	Rabbit	IF – 1AB	1:200
Lmo4	Gift from J. Valsvader		Rat	IF – 1AB	1:500
Fezf2	Thermo Fisher	JP18997	Rabbit	IF – 1AB	1:200
RFP	Abcam	ab124754	Rabbit	IF – 1AB	1:200
RFP	Biomol	600401379S	Rabbit	IF – 1AB	1:500
Doublecortin (DCX)	Santa Cruz Biotechnology	sc-8066	goat	IF – 1AB	1:250
NeuN	Millipore	MAB377	mouse	IF – 1AB	1:500
Ck IgY - AF 488	Thermo Fisher	A11039	Goat	IF – 2AB	1:400
Rb IgG - AF 594	Thermo Fisher	A21428	Goat	IF – 2AB	1:400
Rat IgG - AF 647	Thermo Fisher	A21247	Goat	IF – 2AB	1:400
Rat IgG - AF 488	Thermo Fisher	A11006	Goat	IF – 2AB	1:400
Ck IgY – AF488	Jackson Immunoresearch	703-545-155	Donkey	IF – 2AB	1:200
Rb IgG – Cy3	Dianova	711-165-152	Donkey	IF – 2AB	1:500
Goat IgG – Cy5	Dianova	705-175-147	Donkey	IF – 2AB	1:500
Ms IgG – AF647	Invitrogen	A31571	Donkey	IF – 2AB	1:500
Rat IgG – FP647	Interchim	FP-SC6120	Donkey	IF – 2AB	1:500

***S1 TABLE. Complete list of antibodies used in this study.***